

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
19 July 2001 (19.07.2001)

PCT

(10) International Publication Number  
**WO 01/51490 A1**

(51) International Patent Classification<sup>7</sup>: C07D 471/04,  
487/04, 239/54, 239/56, 239/58, A61P 29/00, 35/00,  
A61K 31/505, 31/52 // (C07D 487/04, 239:00, 235:00)

(74) Agent: PILLAI, Xavier; Leydig, Voit & Mayer, Ltd., 700  
Thirteenth Street, N.W., Suite 300, Washington, DC 20005  
(US).

(21) International Application Number: PCT/US01/00981

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date: 12 January 2001 (12.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/176,373 14 January 2000 (14.01.2000) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): THE  
GOVERNMENT OF THE UNITED STATES OF  
AMERICA, represented by THE SECRETARY, DE-  
PARTMENT OF HEALTH AND HUMAN SERVICES  
[US/US]; National Institutes of Health, Office of Tech-  
nology Transfer, 6011 Executive Boulevard, Suite 325,  
Rockville, MD 20852 (US).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): JACOBSON, Ken-  
neth, A. [US/US]; 1111 University Building W, Apartment  
504, Silver Spring, MD 20902 (US). MARQUEZ, Vic-  
tor, E. [US/US]; 220 Doolittle Street, Montgomery Village,  
MD 20886 (US).

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*



WO 01/51490 A1

(54) Title: METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES

(57) Abstract: The present invention provides novel nucleoside and nucleotide derivatives that are useful agonists or antagonists of P1 or P2 receptors. For example, the present invention provides a compound of formula A-M, wherein A is modified adenine or uracil and M is a constrained cycloalkyl group. The adenine or uracil is bonded to the constrained cycloalkyl group. The compounds of the present invention are useful in the treatment or prevention of various diseases including airway diseases (through A<sub>2B</sub>, A<sub>3</sub>, P2Y<sub>2</sub> receptors), cancer (through A<sub>3</sub>, P2 receptors), cardiac arrhythmias (through A<sub>1</sub> receptors), cardiac ischemia (through A<sub>1</sub>, A<sub>3</sub> receptors), epilepsy (through A<sub>1</sub>, P2X receptors), and Huntington's Disease (through A<sub>2A</sub> receptors).

## METHANOCARBA CYCLOALKYL NUCLEOSIDE ANALOGUES

## CROSS-REFERENCE TO A RELATED APPLICATION

This application claims the benefit of U.S. provisional  
5 application No. 60/176,373, filed January 14, 2000, the  
disclosure of which is incorporated herein by reference.

## TECHNICAL FIELD OF THE INVENTION

This invention pertains to a novel class of receptor  
10 ligands for P1 and P2 receptors and their therapeutic use.  
More specifically, the invention pertains to nucleoside  
derivatives in which the sugar moiety is replaced with a  
cycloalkyl group that is conformationally constrained by  
fusion to a second cycloalkyl group.

15

## BACKGROUND OF THE INVENTION

Purines such as adenosine have been shown to play a wide  
array of roles in biological systems. For example,  
physiological roles played by adenosine include, inter alia,  
20 modulator of vasodilation and hypotension, muscle relaxant,  
central depressant, inhibitor of platelet aggregation,  
regulator of energy supply/demand, responder to oxygen  
availability, neurotransmitter, and neuromodulator. (Bruns,  
Nucleosides & Nucleotides, 10(5), 931-934 (1991)). Because of  
25 its potent actions on many organs and systems, adenosine and  
its receptors have been the subject of considerable drug-  
development research (Daly, J. Med. Chem., 25, 197 (1982)).  
Potential therapeutic applications for agonists include, for

instance, the prevention of reperfusion injury after cardiac ischemia or stroke, and treatment of hypertension and epilepsy (Jacobson, et al., J. Med. Chem., 35, 407-422 (1992)).

Adenosine itself has recently been approved for the treatment  
5 of paroxysmal supra ventricular tachycardia (Pantely, et al., Circulation, 82, 1854 (1990)). Adenosine receptor agonists also find use as anti-arrhythmics, antinociceptives, anti-lipolytics, cerebroprotectives, and antipsychotics.

P2 receptors, are present in heart, skeletal, various  
10 smooth muscles, prostate, ovary, and brain and have been implicated in certain aggregation processes associated with thrombosis and as anti-hypertensive and anti-diabetic agents. Agonists that bind the P2 receptor induce activation of phospholipase C, which leads to the generation of inositol  
15 phosphates and diacyl glycerol with a subsequent rise in intracellular calcium concentration and muscle relaxation. P2 receptor antagonists block ADP-promoted aggregation in platelets and thereby exert an anti-thrombotic effect.

All P1 and P2 receptor nucleoside ligands suffer from  
20 chemical instability that is caused by the labile glycosidic linkage in the sugar moiety of the nucleoside. However, it has been found that relatively few ribose modifications are tolerated by the presently known agonists and antagonists of P1 and P2 receptors.

25 New compositions are needed that have improved chemical stability and that do not destroy the activity of such compounds.

The invention provides such compositions and methods of  
using them in the treatment of disease. These and other  
30 advantages of the present invention, as well as additional

inventive features, will be apparent from the description of the invention provided herein.

#### BRIEF SUMMARY OF THE INVENTION

5       The present invention provides novel nucleoside and nucleotide derivatives that are useful agonists or antagonists of P1 or P2 receptors. The invention is premised upon the novel combination of adenine and uracil and their derivatives with a constrained cycloalkyl group, typically a cyclopentyl  
10       group. The constraint on the cycloalkyl group is introduced by fusion to a second cycloalkyl group. In the case of cyclopentane, the fusion is typically with cyclopropane. The present compounds retain a surprising binding affinity despite the substitution for the ribose group. Moreover, the absence  
15       of the glycosidic bond in the compounds assists in improving the chemical stability of the compounds and aids in overcoming the stability problem associated with the glycosidic bond in previously known P1 and P2 receptor ligands.

      The compounds of the present invention are useful in the  
20       treatment or prevention of various airway diseases (through  $A_{2B}$ ,  $A_3$ ,  $P2Y_2$  receptors), cancer (through  $A_3$ ,  $P2$  receptors), cardiac arrhythmias (through  $A_1$  receptors), cardiac ischemia (through  $A_1$ ,  $A_3$  receptors), epilepsy (through  $A_1$ ,  $P2X$  receptors), Huntington's Disease (through  $A_{2A}$  receptors),  
25       Immunodeficient disorders (through  $A_2$ ,  $A_3$  receptors), inflammatory disorders (through  $A_3$ ,  $P_2$  receptors), neonatal hypoxia (through  $A_1$  receptors), neurodegenerative (through  $A_1$ ,  $A_3$ ,  $P2$  receptors), pain (through  $A_1$ ,  $A_3$ ,  $P2X_3$  receptors), Parkinson's Disease (through  $A_{2A}$  receptors), renal failure  
30       (through  $A_1$  receptors), schizophrenia (through  $A_{2A}$  receptors), sleep disorders (through  $A_1$  receptors), stroke (through  $A_1$ ,  $A_3$ ,

P2 receptors), thrombosis (through P2Y<sub>1</sub>, P2Y<sub>AC</sub> receptors), urinary incontinence (through P2X<sub>1</sub> receptors), diabetes (through A<sub>1</sub> receptors), psoriasis (through P2X receptors), septic shock (through P2 receptors), brain trauma (through A<sub>1</sub> receptors), glaucoma (through A<sub>3</sub> receptors) and congestive heart failure (through P2 receptors).

The invention may best be understood with reference to the accompanying drawings and in the following detailed description of the preferred embodiments.

10

#### DETAILED DESCRIPTION OF THE INVENTION


The present invention provides a new class of nucleoside and nucleotide analogs that serve as selective agonists or antagonists for P1 and P2 receptors.

15 Generally, the compounds of the present invention comprise two basic chemical components designated "A" and "M" which are covalently bonded to one another. Component A comprises adenine or uracil, and component M includes a constrained cycloalkyl group. Preferably the adenine and uracil are chemically modified or substituted with moieties  
20 that allow the compound to bind to a P1 or P2 receptor. To that end any of a wide variety of chemical groups can be used to modify adenine and uracil. Those groups are well known to those of skill in the receptor art. Preferably, when A is purine or a purine derivative, the linkage between A and M is  
25 a chemical bond between the N9 purine nitrogen and the C1 carbon of the cycloalkyl group. Where A is pyrimidine or a pyrimidine derivative, the bond is between N1 pyrimidine nitrogen and the C1 carbon of the cycloalkyl group. The


compounds of the present invention have improved stability and surprising receptor binding affinity.

While not wishing to be bound to any particular theory, it is believed that the constrained cycloalkyl group assists  
5 in improving chemical stability and receptor affinity. Preferably the cycloalkyl groups are capable of adopting a conformation such that the compound can bind to P1 or P2 receptors. As a result, preferred cycloalkyl groups are those that tend to form energetically favorable interactions with P1  
10 and P2 receptors and avoid energetically unfavorable ones, such as unfavorable ionic and/or steric interactions. Further, the cycloalkyl group is derivatized with a bridging group. The constraint restricts the cycloalkyl group to certain conformations that are believed to be beneficial to  
15 binding affinity. The preferred cycloalkyl group is a cyclopentyl group. With cyclopentyl groups the preferred method for introducing a conformational constraint is by derivatizing with a fused cyclopropane bridge. With this modification the cyclopentane ring is believed to be  
20 constrained to mimic the conformation of a rigid furanose ring.

Compounds of the present invention include the compounds shown below in Formulae I and II.



Formula 1



Formula II

Formulae I and II show compounds in which a derivatized or underivatized adenine base is joined to a constrained cyclopentyl group. For purposes of reference, the carbon atom of the cyclopentyl group, M, that is joined to adenine, A, is the C1 carbon and the adenine is joined to M through its N9 nitrogen. In the compounds of Formulae I and II the constrained cyclopentyl group is derivatized with a fused cyclopropane bridge. In Formula I the cyclopropyl group bridges carbon atoms C4 and C6. In Formula II the cyclopropyl group bridges carbon atoms C6 and C1. These distinct bridging patterns constrain the cyclopentyl group into distinct conformations, specifically the N- (northern) conformation as in Formula I and the S- (southern) conformation as in Formula II. These two conformations are thought to mimic the two

biologically active conformations of furanose groups for P1 and P2 receptor binding pockets.

The compounds described by Formulae I and II can be further defined by a variety of suitable modifications to the adenine group. As discussed above, any of a wide variety of chemical groups can be used to form suitable adenine derivatives that comprise the novel compounds of the present invention, provided that the resulting compound is capable of binding to a P1 or P2 receptor. These chemical groups are well known in the art and have been described, for example in U.S. Patent Nos. 5,284,834; 5,498,605; 5,620,676; 5,688,774; and Jacobson and Van Rhee, PURINERGIC APPROACHES IN EXPERIMENTAL THERAPEUTICS, Chapter 6, p. 101 (Jacobson and Jarvis eds., 1997); and Jacobson et al., THE P2 NUCLEOTIDE RECEPTORS, p. 81-107, in THE RECEPTORS (Turner et al. eds. 1998), which are incorporated by reference herein. The combination of the chemically modified adenine and the constrained cycloalkyl group provides a surprising improvement in both chemical stability and binding affinity.

By way of example and not in limitation of the present invention in the compounds of Formulae I and II,  $R_1$  is hydrogen, alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, arylalkyl, acyl, sulfonyl, arylsulfonyl, thiazolyl or bicyclic alkyl;  $R_2$  is hydrogen, halo, alkyl, aryl, arylamino, aryloxy, alkynyl, alkenyl, thioether, cyano, alkylthio or arylalkylthio;  $R_3$ ,  $R_4$ , and  $R_5$ , are each hydrogen, hydroxyl, alkoxy, alkyl, alkenyl, alkynyl, aryl, acyl, alkylamino, arylamino, phosphoryl, phosphonyl, boronyl, or vanadyl, and they can be the same or different;  $R_6$  is hydrogen, alkyl, alkenyl, alkynyl, or aminoalkyl.  $R_7$  is a methylene,



dihalomethyl, carbonyl, or sulfoxide group.  $R_8$  is carbon or nitrogen. At least one of  $R_1$ ,  $R_2$ , and  $R_6$  is not hydrogen. It can be appreciated that various combinations of the above groups are also within the invention provided that they retain  
5 agonist or antagonist activity with a P1 or P2 type receptor.

Where an alkyl, alkenyl, alkynyl group is referenced by itself or as part of another group, the reference is to an uninterrupted carbon chain consisting of no more than 20 carbon atoms. Aryl and cycloalkyl groups contain no more than  
10 8 carbons in the ring.

Reference to alkyl groups is further meant to include straight or branched chain alkyls, arylalkyl, aminoalkyl, haloalkyl, alkylthio or arylalkylthio groups. Alkyls specifically include methyl through dodecyl. Where alkyl  
15 groups are present at position  $R_6$  in adenine, it is preferred that the chain length be no longer than 6 carbons. Arylalkyl groups include, phenylisopropyl, phenylethyl. Aminoalkyl groups can be any suitable alkyl group also containing an amine. Similarly, haloalkyl groups can be any suitable alkyl  
20 group that contains a halo substituent, such as bromo, chloro, fluoro, iodo. Alkylthio includes such moieties as thiomethyl, thiopentyl, thiohexyl, thioheptyl, thiooctyl, thiodecyl, thioundecyl, ethylthioethyl, or 6-cyanoethylthio groups. Alkylthio also is meant to include arylalkylthio such as 2-(p-  
25 nitrophenyl)ethylthio, 2-aminophenylethylthio, 2-(p-nitrophenyl)ethylthio, or 2-aminophenylethylthio.

Cycloalkyls for example cyclopentyl, cyclohexyl, hydroxycyclopentyl.

Alkoxys include for example methoxy groups.

Cycloalkoxys can include cyclopentoxy.

Aryl moieties can be arylalkyl, arylalkylthio, arylsulfonyl, arylamino, aryloxy, heteroaryl, haloaryl, arylurea, arylcarboxamido, heteroarylamino or sulfoaryl.

5 Benzyl groups are one species of aryl group. In addition, the arylalkyls include R-phenylisopropyl or phenylethyl.

Aryloxides can be phenyl, R-phenylisopropyl, phenylethyl, 3,5-dimethoxyphenyl-2-(2-methylphenyl)ethyl and sulfophenyl.

10 Haloaryl can be iodobenzyl among other halogenated aryl groups. Additionally, the heteroaryls include, for example, furans such as tetrahydrofuran.

Acyl groups include carbonyls.

Alkenyl groups are analogous to alkyl groups but include at least one carbon-carbon double bond. When present at the  
15 R<sub>6</sub> group of adenine it is preferred that the carbon chain length be from 2 to 6 carbons.

Similarly, alkynyls are analogous to alkenyl groups but contain at least one triple carbon-carbon bond. As with other groups, when present at the R<sub>6</sub> position of adenine it is  
20 preferred that they are not longer than 6 carbons.

Phosphoryl groups include diphosphoryl, triphosphoryl, thiophosphoryl, thiodiphosphoryl, thiotriphosphoryl, imidodiphosphate, imidotriphosphate, methylene diphosphate, methylenetriphosphate, halomethylene diphosphate,  
25 halomethylene triphosphate, boranophosphate, boranodiphosphate, boranotriphosphate, or phosphorothioate-2-thioether for example.

Thio groups include alkylthio, arylalkylthio, alkenylthio, or arylthios. Alkylthio includes such groups as

thiomethyl, thiopentyl, thiohexyl, thioheptyl, thiooctyl, thiododecyl, thioundecyl, ethylthioethyl, or 6-cyanoethylthio. Alkenylthio includes 5-hexenylthio. Arylthios include 2-(p-nitrophenyl)ethylthio, 2-aminophenylethylthio, 2-(p-nitrophenyl)ethylthio, or 2-aminophenylethylthio.

One example of a suitable thiazolyl is (benzothiazolyl)thio-2-propyl.

Examples of bicycloalkyls include s-endonorbornyl, or carbamethylcyclopentane.


Halo groups include such elements as fluoro, bromo, chloro, or iodo.

It will also be appreciated that any group that may be further substituted can be, and still be within the scope of the invention. For example, all of the  $R_1$  groups except hydrogen can be further substituted. By way of illustration, when  $R_1$  is not hydrogen, it can be further modified by substitutions with any of the following chemical substituents including amino, cyano, alkoxyl, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, acyl, halo, hydroxy, phosphoryl, sulfonyl, sulfonamido, carboxyl, thiohydroxyl, sulfonamido, carboxyl, and carboxamido groups. Similarly, for  $R_2 - R_{10}$ , all of the groups other than hydrogen can be substituted further. Multiple substitutions are also contemplated.


In a preferred embodiment  $R_1$  can be either methyl, cyclopentyl, cyclohexyl, phenyl, R-phenylisopropyl, benzyl, or phenylethyl;  $R_2$  is chloride; and  $R_6$  can be a  $C_1-C_6$  alkylamino,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkenyl,  $C_1-C_6$  alkynyl group.

Other compounds of the present invention include the compounds shown below in Formulae III and IV. The Formulae

show compounds in which a derivatized or underivatized uracil base is joined to a constrained cyclopentyl group.



Formula III



Formula IV

- 5 The compounds defined by formulae III and IV can be further defined by a variety of suitable modifications. For example R<sub>1</sub> can be hydrogen, or an alkyl group; R<sub>2</sub> can be hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkenyl, C<sub>1</sub>-C<sub>6</sub> alkynyl, or a C<sub>1</sub>-C<sub>6</sub> aminoalkyl group; R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, can each independently be the same as discussed
- 10 previously with respect to Formulae I and Formulae II. R<sub>6</sub> and R<sub>7</sub> are each independently either sulfur or oxygen.

Certain compounds of the present invention are ligands of P2 receptors. A variety of P2 receptors are known in the art and the present compounds act at one or more of these, which

15 include for example, P2X and P2Y receptors. These Receptor ligands are compounds that bind receptors, preferably in the binding pocket. In certain embodiments the compound can be a

P2 receptor agonist. In other embodiments the compound can be a P2 receptor antagonist.

Certain compounds of the present invention are ligands for the P1 receptor. A variety of subclasses of P1 receptors are known and various of present compounds act at one or more  
5 these species, which include for example A<sub>1</sub>, A<sub>2</sub>, and A<sub>3</sub> receptors. Certain compounds act as P1 receptor agonists while others appear to act as antagonists.

The compounds of the present invention are useful in the  
10 treatment or prevention of various airway diseases (through A<sub>2B</sub>, A<sub>3</sub>, P2Y<sub>2</sub> receptors), cancer (through A<sub>3</sub>, P2 receptors), cardiac arrhythmias (through A<sub>1</sub> receptors), cardiac ischemia (through A<sub>1</sub>, A<sub>3</sub> receptors), epilepsy (through A<sub>1</sub>, P2X receptors), Huntington's Disease (through A<sub>2A</sub> receptors),  
15 Immunodeficient disorders (through A<sub>2</sub>, A<sub>3</sub> receptors), inflammatory disorders (through A<sub>3</sub>, P<sub>2</sub> receptors), neonatal hypoxia (through A<sub>1</sub> receptors), neurodegenerative (through A<sub>1</sub>, A<sub>3</sub>, P2 receptors), pain (through A<sub>1</sub>, A<sub>3</sub>, P2X3 receptors), Parkinson's Disease (through A<sub>2A</sub> receptors), renal failure  
20 (through A<sub>1</sub> receptors), schizophrenia (through A<sub>2A</sub> receptors), sleep disorders (through A<sub>1</sub> receptors), stroke (through A<sub>1</sub>, A<sub>3</sub>, P2 receptors), thrombosis (through P2Y<sub>1</sub>, P2Y<sub>AC</sub> receptors), urinary incontinence (through P2X<sub>1</sub> receptors), diabetes (through A<sub>1</sub> receptors), psoriasis (through P2X receptors),  
25 septic shock (through P2 receptors), brain trauma (through A<sub>1</sub> receptors), glaucoma (through A<sub>3</sub> receptors), and congestive heart failure (through P2 receptors).

The present invention is further directed to a pharmaceutical composition comprising a pharmaceutically

acceptable carrier and at least one compound selected from the group consisting of the presently described compounds.

The pharmaceutically acceptable excipients described herein, for example, vehicles, adjuvants, carriers or  
5 diluents, are well-known to those who are skilled in the art and are readily available to the public. It is preferred that the pharmaceutically acceptable carrier be one that is chemically inert to the active compounds and one that has no detrimental side effects or toxicity under the conditions of  
10 use.

The choice of excipient will be determined in part by the particular compound of the present invention chosen, as well as by the particular method used to administer the composition. Accordingly, there is a wide variety of suitable  
15 formulations of the pharmaceutical composition of the present invention. The following formulations for oral, aerosol, parenteral, subcutaneous, intravenous, intramuscular, interperitoneal, rectal, and vaginal administration are merely exemplary and are in no way limiting.

20 One skilled in the art will appreciate that suitable methods of utilizing a compound and administering it to a mammal for the treatment of disease states, which would be useful in the method of the present invention, are available. Although more than one route can be used to administer a  
25 particular compound, a particular route can provide a more immediate and more effective reaction than another route. Accordingly, the described methods are merely exemplary and are in no way limiting.

The dose administered to an animal, particularly human  
30 and other mammals, in accordance with the present invention

should be sufficient to effect the desired response. Such responses include reversal or prevention of the bad effects of the disease for which treatment is desired or to elicit the desired benefit. One skilled in the art will recognize that dosage will depend upon a variety of factors, including the age, species, condition or disease state, and body weight of the animal, as well as the source and extent of the disease condition in the animal. The size of the dose will also be determined by the route, timing and frequency of administration as well as the existence, nature, and extent of any adverse side-effects that might accompany the administration of a particular compound and the desired physiological effect. It will be appreciated by one of skill in the art that various conditions or disease states may require prolonged treatment involving multiple administrations.

Suitable doses and dosage regimens can be determined by conventional range-finding techniques known to those of ordinary skill in the art. Generally, treatment is initiated with smaller dosages that are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. The present inventive method typically will involve the administration of about 0.1 to about 300 mg of one or more of the compounds described above per kg body weight of the individual.

The following examples further illustrate the present invention but, of course, should not be construed as in any way limiting its scope. In the examples, unless otherwise noted, compounds were characterized and resonances assigned by 300

MHz proton nuclear magnetic resonance mass spectroscopy using a Varian GEMINI-300 FT-NMR spectrometer. Also, unless noted otherwise, chemical shifts are expressed as ppm downfield from tetramethylsilane. Synthetic intermediates were characterized by chemical ionization mass spectrometry ( $\text{NH}_3$ ) and adenosine derivatives by fast atom bombardment mass spectrometry (positive ions in a noba or m-bullet matrix) on a JEOL SX102 mass spectrometer. Low resolution CI- $\text{NH}_3$  (chemical ionization) mass spectra were carried out with Finnigan 4600 mass spectrometer and high-resolution EI (electron impact) mass spectrometry with a VG7070F mass spectrometry at 6kV. Elemental analysis was performed by Atlantic Microlab Inc. (Norcross, GA). NMR and mass spectra were consistent with the assigned structure.

15

## EXAMPLE 1

In all of the potent adenosine agonists previously developed, the ribose moiety is present, and consequently, these agonists are subject to deglycosylation and other pathways of metabolic degradation in vivo. In order to design non-glycosyl adenosine agonists and thereby increase biological stability and potential receptor selectivity, carbocyclic modifications of the ribose moiety have been introduced. In previous studies of adenosine analogues it was found that if adenosine derivatives having carbocyclic modifications of the ribose ring (compounds 1-4, below)

25


bind to adenosine receptors it is only with greatly reduced affinity.

In the present study we have incorporated a complex carbocyclic modification of ribose for use with adenosine


30




agonists. This modification, wherein only one isomeric form retains high affinity and receptor selectivity, is the "methanocarba" ring. In this modification a fused cyclopropane ring constrains the accompanying cyclopentane moiety to mimic the conformation of a rigid furanose ring. The furanose ring of nucleosides and nucleotides in solution is known to exist in a rapid, dynamic equilibrium between a range of Northern and opposing Southern conformations as defined in the pseudorotational cycle. For methanocarba analogues, the bicyclo[3.1.0]hexane ring can constrain the cyclopentane ring into a N-, 2'-exo envelope pucker, and a S-, 3' exo form.

1, R = C<sub>6</sub>H<sub>5</sub>NH, CGS 23321


5b, R = H, aristeramycin



2, AMP 579



3, MRS 582




4, MDL 201,449

These two extreme forms of ring pucker usually define biologically active conformations. This example shows that nucleoside binding to P1- (adenosine) receptors, is favored when the fixed ring-twist conformation is in the N- conformation.

20 Chemical Synthesis.

Nucleosides and synthetic reagents were purchased from Sigma Chemical Co. (St. Louis, MO) and Aldrich (St. Louis, MO). 2,6-Dichloropurine was obtained from Sigma. *m*-iodobenzyl bromide was purchased from Aldrich (St. Louis, MO). 4-(6-Aminopurin-9-yl)-1-hydroxymethyl-bicyclo[3.1.0]hexane-2,3-diol (1) and compounds 5c and 5d were obtained from Dr. Victor Marquez. Compounds 7a and 9a were synthesized in our laboratory.

The synthetic strategy used in this example is shown below. The synthesis of N6-substituted N-methanocarba adenosine derivatives optimized for interaction with A1 (CP = cyclopentyl) or A3 (IB = 3-iodobenzyl) receptors. Reagents: a) DEAD,  $\text{Ph}_3\text{P}$ ; b)  $\text{MeOH}$ , rt; c)  $\text{BCl}_3$ ; d)  $\text{H}_2/\text{Pd}$ ; e) 3-iodobenzyl bromide,  $50^\circ\text{C}$ ,  $\text{DMF}$ , 2 days; f)  $\text{NH}_4\text{OH}$ ,  $\text{MeOH}$ ,  $80^\circ\text{C}$ , 3 days.



(1'R, 2R, 3'R, 4'R, 1'aR)-2,3-(dihydroxy)-4-(hydroxymethyl)-1-(6-cyclopentylaminopurine-9-yl)bicyclo(3.1.0)hexane (6c):

A solution of 8c (4 mg, 0.01 mmol) in methanol (0.5 ml) was hydrogenated at atmospheric pressure over 10% Pd/C (1 mg) to  
5 furnish the product 6c (83% yield).  $^1\text{H}$ NMR ( $\text{CD}_3\text{OD}$ ):  $\delta$  0.7-0.8 (m, 1H, 6'-CHH), 1.46-1.88 (m, 1OH, 6'CHH, 1'aH, 4CH<sub>2</sub>), 2.01-2.20 (m, 1H, NCH), 3.34 (d, 1H, J = 9.77 Hz, 5'CHH), 3.88 (d, 1H, J = 6.84 Hz, 3'CH), 4.26 (d, 1H, J = 9.77 Hz, 5'CHH), 4.66-4.98 (m, 2H, 2'CH, 1'CH), 8.28 (s, 1H, 2CH), 8.5 (s, 1H, 8CH). HRMS (FAB): Cal: 346.1879 Found: 346.1879

(1'R, 2'R, 3'R, 4'R)-2,3-(dihydroxy)-4-(hydroxymethyl)-1-(6-(3-iodobenzylamino)purine-9-yl)cyclopentane (7b):

A mixture of aristeromycin (3.5 mg, 0.013 mmol) and 3-iodobenzylbromide (12 mg, 0.039 mmol) in anhydrous DMF was  
15 heated for 3 days, and solvent was removed under vacuum. The excess 3-iodobenzylamine was removed from the reaction mixture by adding ether to the reaction mixture, and stirring was continued for 5 min. followed by decantation of the supernatant ether phase. The residue was dried, suspended in  
20 methanol (1 ml) and ammonium hydroxide (0.5 ml), and heated at 80 °C in a closed tube for 1 h. Solvent was removed under vacuum, and the residue obtained was purified by flash column chromatography using 7/3 chloroform/methanol to furnish 3.0 mg (47%) of the product.

25  $^1\text{H}$ NMR ( $\text{CD}_3\text{OD}$ )  $\delta$  1.86-1.96 (m, 1H, 1'CHH), 2.14-2.30 (m, 1H, 1'CHH), 2.38-2.48 (m, 1H, 4'CH), 3.3-3.38 (m, 1H, 5'CHH), 3.67 (d, 1H, J = 6.84 Hz, 5'CHH), 3.96-4.06 (m, 1H, 3'CH), 4.43-4.48 (m, 1H, 2'CH), 4.73-4.82 (m, 1H, 1'CH), 5.26 (s, 2H, ArCH<sub>2</sub>), 7.12 (t, 1H, J = 7.82 Hz, ArH), 7.32 (d, 1H, J =

7.82Hz, ArH), 7.66 (d, 1H,  $J = 7.82$  Hz, ArH), 7.73 (s, 1H, ArH), 8.06 (s, 1H, 2CH). 8.08 (s, 1H, 8CH).

Preparation of 4-[6-(3-iodobenzylamino)-purin-9-yl]-1-hydroxymethyl-bicyclo[3.1.0]hexane-2,3-diol (7c, (N)-

5 Methanocarpa-N<sup>6</sup>-(3-iodobenzyl)adenosine) by Dimroth rearrangement:<sup>1</sup>

To a solution of 4-(6-amino-purin-9-yl)-1-hydroxymethyl-bicyclo[3.1.0]hexane-2,3-diol (5c, 20 mg, 0.0721 mmol) in DMF (0.5 mL) was added *m*-iodobenzyl bromide (64 mg, 0.216 mmol),  
10 and the mixture was stirred at 50 °C for 2 days. DMF was then removed under a stream of N<sub>2</sub>. To the resulting syrup 0.5 mL of acetone and 1 mL of ether were added and the syrup solidified. The solvents were removed by decantation, and again ether was added and removed. The solid was dried and  
15 dissolved in 1 mL MeOH. NH<sub>4</sub>OH (1.5 mL) was added and the mixture was stirred at 80 °C for 3 days. After cooling down to room temperature, the solvents were removed under reduced pressure and the residue was purified by preparative TLC (silica 60; 1 000 µm; Analtech, Newark, DE; ethyl acetate-*i*-  
20 PrOH-H<sub>2</sub>O (8:2:1)) to give 26 mg of the product (7c), yield: 73 %. <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.82 (t,  $J = 6.0$  Hz, 1 H), 1.41 (t,  $J = 4.8$  Hz, 1 H), 1.72 (dd,  $J = 8.5, 6.0$  Hz, 1H), 3.36 (d,  $J = 10.8$  Hz, 1 H), 4.05 (d,  $J = 6.9$  Hz, 1 H), 4.33 (m, 1 H), 4.80-4.88 (m, 3 H), 5.21 (d,  $J = 6.9$  Hz, 1 H), 6.25 (m, br, 1),  
25 7.07 (t,  $J = 7.8$  Hz, 1 H), 7.35 (d,  $J = 7.8$  Hz, 1 H), 7.61 (d,  $J = 7.8$  Hz, 1 H), 7.74 (s, 1), 7.93 (s, 1 H), 8.33 (s, 1 H). MS (FAB):  $m/z$  494 (M<sup>+</sup>+I).

(1'R, 2'R, 3'R, 4'R, 1'aR,)-2,3-(dihydroxy)-4-(hydroxymethyl)-  
1-(2-chloro-6-cyclopentylaminopurine-9-  
yl)bicyclo(3.1.0)hexane) (8c):

To a solution of 15 (36 mg, 0.076 mmol) in anhydrous  
5 dichloromethane was added BCl<sub>3</sub> (1M solution in  
dichloromethane, 0.23 ml, 0.23 mmol) at 0 °C. The reaction  
mixture was warmed to room temperature and stirred for 10 min.  
To this mixture was added methanol (1 ml) followed by ammonium  
hydroxide (0.5 ml). The mixture was concentrated under  
10 vacuum, and the residue obtained was purified by flash column  
chromatography using 9/1 chloroform-1/methanol as eluent to  
furnish 14 mg of the product 8c (48% yield) as a solid.

<sup>1</sup>H NMR(CDCl<sub>3</sub>): δ 0.65-0.9 (m, 1H, 6'CHH), 1.1-1.4 (m, 2H, 6'CHH,  
1'aH), 1.4-1.9 (m, 8H, 4CH<sub>2</sub>), 2.0-2.2 (m, 1H, N<sup>6</sup>CH), 3.34 (d,  
15 1H, J = 7.2 Hz, 5'CHH), 3.97 (d, 1H, J = 4.6 Hz, 3'CH), 4.25  
(d, 1H, J = 7.2 Hz, 5'CHH), 4.687 (s, 1H, 1'CH), 5.11 (d, 1H,  
J 4.6, 2'CH), 7.85 (s, 1H, 8CH). HRMS(FAB): Cal: 380.1489  
found: 380.1498

(1'R, 2'R, 3'R, 4'R, 1'aR)-2,3-(dihydroxy)-4-(hydroxymethyl)-  
20 1-(2-chloro-6-(3-idobenzylamino)purine-9-  
yl)bicyclo(3.1.0)hexane) (9c) was synthesized by the same  
method as 8c in 53% yield.

<sup>1</sup>H NMR(CD<sub>3</sub>OD): δ 0.70-0.78 (m, 1H, 6'CHH), 1.50-1.63 (m, 2H,  
6', CHH, 1'aH), 3.33 (d, 1H, J = 11.72 Hz, 5'CHH), 3.88 (d, 1H,  
25 J = 6.84 Hz, 3'CH), 4.26 (d, 1H, J = 11.72 Hz, 5'CHH), 4.71-  
4.83 (m, 2H, 1'CH, 2'CH), 7.1 (t, 1H, J = 7.82 Hz, ArH), 7.40  
(d, 1H, J = 7.82 Hz, ArH), 7.61 (d, 1H, 7.82 Hz, ArH), 7.78  
(s, 1H, ArH), 8.54 (s, 1H, 8CH). HRMS(FAB): Cal: 528.0299  
Found: 528.0295

(2R, 3R, 4R, 1'aR, 1S)-2,3-(O-isopropylidene)-4-(methylenebenzoyloxy)-1-(2,6dichloropurine-9-yl)bicyclo(3.1.0)hexane) (12):

To a solution of triphenyl phosphine (260 mg, 1 mmol) in anhydrous THF (2 ml) was added DEAD (0.16 ml, 1 mmol) dropwise at 0 °C, and stirring was continued for 20 min. To this solution was added a solution of 2,6-dichloropurine in THF (4 ml) followed by the addition of 11 (145 mg, 0.5 mmol) in THF (4 ml). The reaction mixture was warmed to room temperature, and stirring was continued for 6 h. Solvent was evaporated under vacuum, and the residue obtained was purified by flash chromatography using 7/3 petroleum ether/ethylacetate as eluent to furnish 141 mg of the product (12) (70% yield) as a gum.

$^1\text{H}$ NMR ( $\text{CDCl}_3$ ):  $\delta$  1.0 (m, 1H, 6'CHH), 1.24 (s, 3H,  $\text{CH}_3$ ), 1.27-1.38 (m, 1H, 6'CHH), 1.55 (s, 3H,  $\text{CH}_3$ ), 1.62 (dd, 1H,  $J = 4.88$ , 9.77 Hz, 1'aH), 3.34 (d, 1H,  $J = 9.77$  Hz, 5'CHH), 3.97 (d, 1H,  $J = 9.77$  Hz, 5'CHH), 4.50 (d, 1H,  $J = 6.84$  Hz, 3'CH), 4.57-4.68 (qAB, 2H,  $J = 12.7$  Hz,  $\text{ArCH}_2$ ), 5.17 (s, 1H, 1'CH), 5.32 (d, 1H,  $J = 6.84$  Hz, 2'H), 7.27-7.4 (m, 5H, Ar), 8.63 (s, 1H, 8CH).  
(2R, 3R, 4R, 1'aR, 1S)-2,3-(O-isopropylidene)-4-(methylenebenzoyloxy)-1-(2-chloro-6-cyclopentylaminopurine-9-yl)bicyclo(3.1.0)hexane) (15):

To a solution of 12 (42 mg, 0.105 mmol) in methanol (2 ml) was added cyclopentylamine at room temperature, and stirring was continued for 6 hr for complete reaction. Solvent was removed under vacuum, and the residue obtained was purified by flash column chromatography using 7/3 petroleum ether/ethylacetate as eluent to furnish 45 mg of the product 15 (90% yield) as a gum.

$^1\text{H NMR}(\text{CDCl}_3)$ :  $\delta$  0.92-0.96 (m, 1H, 6' $\underline{\text{CHH}}$ ), 1.14-1.01 (m, 1H, 6' $\underline{\text{CHH}}$ ), 1.23 (s, 3H,  $\text{CH}_3$ ), 1.42-1.81 (m, 9H, 1'aH, 4 $\text{CH}_2$ ), 1.54 (s, 3H,  $\text{CH}_3$ ), 2.08-2.21 (m, 1H, N<sup>6</sup>  $\underline{\text{CH}}$ ), 3.44 (d, 1H,  $J = 9.76$  Hz, 5' $\underline{\text{CHH}}$ ), 3.90 (d, 1H,  $J = 9.76$  Hz, 5' $\underline{\text{CHH}}$ ), 4.51 (d, 1H,  $J = 6.84$  Hz, 3' $\underline{\text{CH}}$ ), 4.57-4.67 (qAB, 2H,  $J = 12.7$  Hz,  $\text{ArCH}_2$ ), 5.04 (s, 1H, 1' $\underline{\text{CH}}$ ), 5.32 (d, 1H,  $J = 6.84$  Hz, 2' $\underline{\text{CH}}$ ), 7.2-7.4 (m, 5H, Ar), 8.18 (s, 1H, 8CH).

(1'R, 2'R, 3'R, 4'R, 1'aR)-2,3-(O-isopropylidene)-4-(methylenebenzoyloxy)-1-(2-chloro-6-(3-iodobenzylamino)purine-9-yl)bicyclo(3.1.0)hexane (16) was synthesized in 70% yield by the same method as 15, except using 3-iodobenzylamine hydrochloride and two equivalents of triethylamine.

$^1\text{H NMR}(\text{CDCl}_3)$ :  $\delta$  0.87-0.91 (m, 1H, 6' $\underline{\text{CHH}}$ ), 1.10-1.29 (m, 1H, 6' $\underline{\text{CHH}}$ ), 1.17 (s, 3H,  $\text{CH}_3$ ), 1.42-1.56 (m, 1H, 1'aH), 1.47 (s, 3H,  $\text{CH}_3$ ), 3.37 (d, 1H,  $J = 9.77$  Hz, 5' $\underline{\text{CHH}}$ ), 3.84 (d, 1H,  $J = 9.77$  Hz, 5' $\underline{\text{CHH}}$ ), 4.44 (d, 1H,  $J = 6.84$  Hz, 3' $\underline{\text{CH}}$ ), 4.50-4.60 (qAB, 2H,  $J = 11.72$  Hz,  $\text{ArCH}_2$ ), 4.70 (bs, 1H, NH), 4.98 (s, 1H, 1' $\underline{\text{CH}}$ ), 5.24 (d, 1H,  $J = 6.84$  Hz, 2' $\underline{\text{CH}}$ ), 7.0 (t, 1H,  $J = 7.82$  Hz, ArH), 7.2-7.34 (m, 6H, ArH), 7.55 (d, 1H,  $J = 7.82$ , ArH), 7.65 (s, 1H, ArH), 8.08 (s, 1H, 8CH).

#### Pharmacological Analyses.

##### Materials

F-12 (Ham's) medium, fetal bovine serum (FBS) and penicillin/streptomycin were from Gibco BRL (Gaithersburg, MD). [<sup>125</sup>I]AB-MECA (1000 Ci/mmol) and [<sup>35</sup>S]guanosine 5'-( $\gamma$ -thio)triphosphate (1000-1500 Ci/mmol) were from DuPont NEN (Boston, MA). Adenosine deaminase (ADA) was from Boehringer Mannheim (Indianapolis, IN). All other materials were from

standard local sources and of the highest grade commercially available.

#### Cell culture and membrane preparation

5 CHO cells stably transfected with either human A<sub>1</sub> or A<sub>3</sub> receptors (gift of Dr. Gary Stiles and Dr. Mark Olah, Duke University Medical Center) were cultured as monolayers in medium supplemented with 10% fetal bovine serum. Cells were washed twice with 10 ml of ice-cold phosphate buffered saline,  
10 lysed in lysis buffer (10 mM Tris.HCl buffer, pH 7.4, containing 2 mM MgCl<sub>2</sub> and 0.5 mM EDTA), and homogenized in a Polytron homogenizer in the presence of 0.2 U/ml adenosine deaminase. The crude membranes were prepared by centrifuging the homogenate at 1000 x g for 10 min followed by  
15 centrifugation of the supernatant at 40,000 x g for 15 min. The pellet was washed once with the lysis buffer and recentrifuged at 40,000 x g for 15 min. The final pellets were resuspended in 50 mM Tris.HCl buffer, pH 7.4, containing 10 mM MgCl<sub>2</sub> and 0.1 mM EDTA and stored at -70 °C.

20

#### Radioreceptor Binding

Determination of binding to adenosine A<sub>1</sub>, A<sub>2A</sub> and A<sub>2B</sub> receptors was carried out as reported. Determination of A<sub>3</sub> adenosine receptor binding was carried out using [<sup>125</sup>I]AB-MECA. Briefly,  
25 aliquots of crude transfected CHO cell membranes (approximately 40 µg protein/tube) were incubated with 0.5 nM [<sup>125</sup>I]AB-MECA, 10 mM MgCl<sub>2</sub>, 2 units/ml adenosine deaminase, 50 mM Tris.HCl (pH 7.4) at 37 °C for 60 min. The total volume of the reaction mixture was 125 µl. Bound and free ligands were  
30 separated by rapid filtration of the reaction mixture through



Whatman GF/B glass filters. The filters were immediately washed with two 5 ml-portions of ice-cold 50 mM Tris.HCl buffer (pH 7.4). The radioactivity bound to the filters was determined in a Beckman gamma counter. Specific binding was defined as the amount of the radioligand bound in the absence of competing ligand minus the amount of that bound in the presence of 100  $\mu$ M NECA.  $K_i$ -values were calculated using the  $K_d$  for [ $^{125}$ I]AB-MECA binding of 0.56 nM.

#### 10 Determination of [ $^3$ S]GTP $\gamma$ S Binding

[ $^{35}$ S]GTP $\gamma$ S binding was determined by the method of Lorenzen et al. The incubation mixture contained in a total volume of 125  $\mu$ l, 50 mM Tris.HCl (pH 7.4), 1 mM EDTA, 10 mM MgCl<sub>2</sub>, 10  $\mu$ M guanosine 5'-diphosphate, 1 mM dithiothreitol, 100 mM NaCl, 0.2 units/ml adenosine deaminase, 0.16 nM [ $^{35}$ S] GTP $\gamma$ S (about 50,000 cpm) and 0.5% BSA. The CHO cell membranes expressing A<sub>1</sub> or A<sub>3</sub> receptors were preincubated with the above-mentioned assay mixture at 37 °C for 1 h and further incubated for 1 hr after the addition of [ $^{35}$ S]GTP $\gamma$ S. Incubations were terminated by rapid filtration of the samples through glass fiber filters (Whatman GF/B), followed by two 5 ml washes of the same buffer. After transferring the filters into a vial containing 3 ml of scintillation cocktail, the radioactivity was determined in a scintillation counter.

25

*Data analysis.* Analyses of saturation binding assays and concentration-response curves were carried out using the GraphPad Prism (GraphPad Software Inc., San Diego, CA). Comparisons between groups were carried out using the unpaired Student's test.

30

## RESULTS

### Chemical synthesis

The methanocarbo-cyclic 2'-deoxyadenosine analogues, shown below in Table 1, in which a fused cyclopropane ring constrains the cyclopentane ring into a rigid envelope configuration of either a *N*- or *S*- conformation, were synthesized in a manner similar as shown above. The *N*-methanocarba analogues of various N<sup>6</sup>-substituted adenosine derivatives, including cyclopentyl and iodobenzyl, in which the parent compounds are potent and selective agonists at either A<sub>1</sub> or A<sub>3</sub> receptors, respectively, were prepared. 2,6-Dichloropurine, 10, was condensed with the cyclopentyl derivative, 11, using the Mitsunobu reaction, followed by substitution at the 6-position and deprotection to give 8c or 9e. The 2-chloro substitution of compound 8c was removed by catalytic reduction to give 6c. This allowed the incorporation in the *N*-configuration series of the 2-chloro modification of adenine, which was of interest for its effect on adenosine receptor affinity. An N<sup>6</sup>-(3-iodobenzyl) group could also be introduced in either aristeromycin, 5b, or *N*-methanocarba-adenosine, 5c, by the Dimroth rearrangement, to give 7b and 7c.

### Biological activity

A pair of methanocarba analogues of adenosine, 5c and 5d, corresponding to *N*- and *S*- conformations of ribose, were tested in binding assays, the results of which are shown in Table 1 below, at four subtypes of adenosine receptors. The more synthetically challenging *S*-isomer (5d) was available

only as the racemate and therefore was tested as such. At rat A1, rat A2A, and human A3 subtypes, the N-analogue proved to be of much higher affinity than the S-analogue. At the human A2B receptor, binding was carried out using [3H]ZM 241,385, however the affinity was too weak to establish selectivity for a specific isomer. Affinity of N-methanocarpa-adenosine, 5c, vs. adenosine, 5a, was particularly enhanced at the A3 receptor subtype, for which the ratio of affinities of N-to S-analogues was 150-fold. Although a poor substrate for adenosine deaminase (ADA), the binding curve for 5c was shifted in the presence of ADA, therefore the affinity values for 5c and 5d obtained in the absence of ADA are entered in Table 1, below. The South conformer, 5d, is even a worse substrate of ADA (100-fold less) which explains why the curves in the presence and absence of ADA for 5d are virtually the same. Aristeromycin, 5b, bound weakly to adenosine receptors, with slight selectivity for the A<sub>2A</sub> subtype. Compound 5c was more potent than aristeromycin, 5b, in binding to A1 (4-fold) and A3 (4500-fold) adenosine receptors.

Compounds 6c and 8c are patterned after A1 receptor-selective agonists, while compounds 7c and 9c are patterned after A3 receptor-selective agonists. Compounds 6 and 7 are unsubstituted at the 2-position, while compounds 8 and 9 contain the potency enhancing 2-chloro substituent. The N6-cyclopentyl N-methanocarpa derivative, 6c, based on CPA, 6a, maintained high selectivity for A1 receptors, although the affinity of 6c at rat A1 receptors was 3-fold less than for 6a. In one series it was possible to compare ribose, cyclopentyl, and N-methanocarpa derivatives having the same N6-substitution. The N6-(3-iodobenzyl) derivative, 7c, based on a 5'-hydroxy analogue, 7a, of IB-MECA, with a K<sub>i</sub> value of

4.1 nM was 2.3-fold more potent at A3 receptors than the ribose-containing parent. Thus, the selectivity of 7c for human A3 versus rat A1 receptors was 17-fold. The aristeromycin analogue, 7b, was relatively weak in binding to  
5 adenosine receptors.


Among 2-chloro-substituted derivatives, the N-methanocarba analogue, 8c, was less potent at A1 and A2A receptors than its parent 2-chloro-N6-cyclopentyladenosine, 8a, and roughly equipotent at A3 receptors. Thus, 8c was 53-  
10 fold selective in binding to rat A1 vs. human A3 receptors. The N-methanocarba analogue, 9c, of 2-chloro-N6-(3iodobenzyl)adenosine, 9a, had  $K_i$  values (nM) of 141, 732, and 2.2 at A1, A2A, and A3 receptors, respectively. Thus, the 2-chloro group slightly enhanced affinity at A3 receptors,  
15 while reducing affinity at A1 receptors.

The receptor binding affinity upon replacement of ribose with the N-methanocarba moiety was best preserved for the A3 subtype, at which differences were small. At A1 receptors the loss of affinity for structures 6 - 9 was between 3- and 8-  
20 fold. At A2A receptors the loss of affinity was between 6- and 34-fold.

The agonist-induced stimulation of binding of guanine nucleotides to activated G-proteins has been used as a functional assay for a variety of receptors, including  
25 adenosine receptors. Binding of [ $^{35}$ S]GTP- $\gamma$ -S was studied in membranes prepared from CHO cells stably expressing human A1 or A3 receptors (Table 2). The non-selective adenosine agonist NECA (5'-N-ethyluronamidoadenosine) caused a concentration-dependent increase in the level of the guanine  
30 nucleotide bound. Compound 6c was highly selective and a full agonist at human A1 but not rat A1 receptors. Both 7c and 9c

stimulated the binding of [<sup>35</sup>S]GTP-γ-S, however the maximal stimulation was significantly less than that produced by either NECA or N6-(3-iodobenzyl)adenosine, 7a, both being full A3 agonists. Compounds 7c and 9c resulted in relative stimulation of [<sup>35</sup>S]GTP-γ-S binding of only 45% and 22%, respectively, indicating that the efficacy of the N-methanocarba analogue at A3 receptors was further reduced upon 2-chloro modification. The potency of compounds 7c and 9c, indicated by the EC50 values in this functional assay, was greater than the potencies of either NECA or compound 7a (Table 2). Thus, the N-methanocarba N6-(3-iodobenzyl) analogues appear to be highly potent and selective partial agonists at human A3 receptors.

Table I  
Affinities of Adenosine Derivatives<sup>1</sup>



$K_i$  (nM) or % displacement

Compound	R'	R	$RA_{50}^a$	$RA_{50}^b$	$hA_{50}^c$
1a	H	cyclopentyl	0.59	462	274±20
CPA					240 (r)
1b	H	cyclopentyl	5.06±0.51	6800±1800	170±51
1781					
1c	H	cyclopentyl	5110±790	15% at 10 $\mu$ M	
1783					
2a	H	3-iodobenzyl	20.0±8.5	17.5±0.5	9.5±1.4 (r)
IBO-ADO, 541					
2b	H	3-iodobenzyl	69.2±9.8	601±236	4.13±1.76

1743									
3a	C1	cyclopentyl	0.6	950	237 (r)				
CCPA									
3b	C1	cyclopentyl	8.76±0.81	3390±520	466±58				
1761									
3c	C1	cyclopentyl	3600±780	45±5% at 100 µM					
1782									
4a	C1	3-iodobenzyl	18.5±4.7	38.5±2.0	1.41±0.17 (r)				
542									
4b	C1	3-iodobenzyl	141±22	732±207	2.24±1.45				
1760									
4c	C1	3-iodobenzyl	8730±370	25,400±3800					
1784									

Compound	R <sub>2</sub>	RA <sup>a</sup> 10 <sup>4</sup>	RA <sup>b</sup> 30 <sup>d</sup>	hA <sup>b</sup> 100 µM	hA <sup>b</sup> 1000 (r) d,e	A <sub>2</sub> /A <sub>1</sub>
5a	H	Estd. 10 <sup>d</sup>	estd. 30 <sup>d</sup>	<10% at 100 µM	estd. 1000 (r) d,e	100
5b	H	6260±730	2150±950	47,300±10,600	20,000±7900 (r) e	0.31
5c	H	1680±80	22,500±100 (h) <sup>e,f</sup>	35±2% at 50 µM <sup>f</sup>	404±70 <sup>f</sup>	4.2

5d	H	15% at 100 $\mu$ M	>100,000 (h) <sup>c,f</sup>	20 $\pm$ 4% at 50 $\mu$ M <sup>f</sup>	62,500 $\pm$ 2900 <sup>f</sup>	>1
(racemic)						
6a	CP	1.50 $\pm$ 0.51	857 $\pm$ 163	21,200 $\pm$ 4300	274 $\pm$ 20, 240 (r) <sup>e</sup>	0.0055
6c	CP	5.06 $\pm$ 0.51	6800 $\pm$ 1800	139k $\pm$ 19k	170 $\pm$ 51	0.030
7a	IB	20.0 $\pm$ 8.5	17.5 $\pm$ 0.5	3570 $\pm$ 100	9.5 $\pm$ 1.4 (r) <sup>e</sup>	2.1
7b	IB	25,900 $\pm$ 1600	<10% 100 $\mu$ M	n.d.	1960 $\pm$ 370	13
7c	IB	69.2 $\pm$ 9.8	601 $\pm$ 236	12,100 $\pm$ 1300	4.13 $\pm$ 1.76	17
8a	CP	1.33 $\pm$ 0.19	605 $\pm$ 154	20,400 $\pm$ 1200	237 (r) <sup>e</sup>	0.0056
8c	CP	8.76 $\pm$ 0.81	3390 $\pm$ 520	27 $\pm$ 7% at 100 $\mu$ M	466 $\pm$ 58	0.019
9a	IB	18.5 $\pm$ 4.7	38.5 $\pm$ 2.0	5010 $\pm$ 1400	1.41 $\pm$ 0.17 (r) <sup>e</sup>	13
9c	IB	141 $\pm$ 22	732 $\pm$ 207	41,000 $\pm$ 700	2.24 $\pm$ 1.45	63

31

<sup>1</sup> (a) simple carbocyclic, (b) and methanocarba-adenosine (N)-conformation; (c) and S-conformation, (d) derivatives in radioligand binding assays at rat A<sub>1</sub>,<sup>a</sup> rat A<sub>2A</sub>,<sup>b</sup> human A<sub>2A</sub>,<sup>b</sup> and human A<sub>3</sub> receptors,<sup>c</sup> unless noted.<sup>e</sup>



TABLE II

Effect of ligands to stimulate [ $^{35}$ S]GTP $\gamma$ S binding to membranes of cells expressing the cloned hA<sub>1</sub>AR or hA<sub>2</sub>AR or in rat cerebral cortical membranes containing the A<sub>1</sub>AR

Ligand	cloned hA <sub>1</sub> AR EC <sub>50</sub> (nM) <sup>a</sup>	% Maximal Stimulation <sup>c</sup>	rat A <sub>1</sub> AR EC <sub>50</sub> (nM) <sup>a</sup>	% Maximal Stimulation <sup>c</sup>	cloned hA <sub>2</sub> AR EC <sub>50</sub> (nM) <sup>a</sup>	% Maximal Stimulation <sup>c</sup>
NECA	n.d.		n.d.		155±15	100
6a	4.15 ± 0.90	100	20.3 ± 13.1	100	7980 ± 60	100
6c	21.5 ± 2.3	102 ± 1	100 ± 17	75 ± 6	>10,000	14±2% at 10 $\mu$ M
7a	43.1 ± 10.4	91 ± 1	340 ± 98	95 ± 4	5.16 ± 0.71	100
7b	>10,000	5±2% at 10 $\mu$ M	n.d.		>10,000	15±5% at 10 $\mu$ M
7c	218 ± 18	86 ± 2	940 ± 114	55 ± 5	0.70 ± 0.16	45.3 ± 6.8
8c	31.2 ± 3.3	97 ± 1	145 ± 35	96 ± 2	n.d.	
9c	142 ± 24	91 ± 1	684 ± 75	48 ± 3	0.67 ± 0.19	22.0 ± 2.8

<sup>a</sup> EC<sub>50</sub> for stimulation of basal [ $^{35}$ S]GTP $\gamma$ S binding by agonists in membranes from transfected CHO cells ( $\pm$ S.E.M.), n = 3.

n.d. not determined.

5

## Discussion

Nearly all of the thousands of known adenosine agonists are derivatives of adenosine. Although molecular modeling of adenosine agonists has been carried out, there has been no direct evidence from this for a conformational preference of the ribose ring in the receptor binding site. In the present study, methanocarba-adenosine analogues have defined the role of sugar puckering in stabilizing the active receptor-bound conformation. The S-methanocarba analogue of adenosine, 5d, was only weakly active, presumably because of a disfavored conformation that decreases receptor binding. In contrast, the methanocarba analogues constrained in the N-conformation, e.g. 5c - 9c, displayed high receptor affinity, particularly at the A<sub>3</sub> receptor. In binding assays at A<sub>1</sub>, A<sub>2A</sub>, and A<sub>3</sub> receptors, N-methanocarba-adenosine proved to be of higher

20

affinity than the S-analogue, with an N:S-affinity ratio of 150 at the human A3 receptor. Thus, the biological potency and efficacy of this series of nucleosides appears to be highly dependent on ring puckering, which in turn would influence the orientation of the hydroxyl groups within the receptor binding site.

The structure activity relationship (SAR) of adenosine agonists indicates that the ribose ring oxygen may be substituted with carbon, as in 5b and 7b, however much affinity is lost. As demonstrated with the aristeromycin derivative, 7b, simple carbocyclic substitution of the ribose moiety of otherwise potent, N6-substituted adenosine agonists greatly diminishes affinity, even in comparison to aristeromycin, 5b.

In comparison to the ribose analogues, the N-methanocarba N6-substituted adenosine agonists were of comparable affinity at A3 receptors, but less potent at A1, A2A, and A2B receptors. The N-methanocarba N6-cyclopentyl derivatives were A1 receptor-selective and maintained high efficacy at human recombinant but not rat brain A1 receptors; as indicated by stimulation of binding of [<sup>35</sup>S]GTPγS. This may be related to either species differences or heterogeneity of G proteins, since the degree of agonist efficacy of a given compound may be highly dependent on the receptor-associated G protein. N-Methanocarba N6-(3-iodobenzyl)adenosine and the 2-chloro derivative had K<sub>i</sub> values of 4.1 and 2.2 nM at A3 receptors, respectively, and were selective partial agonists. As for the ribose parents, additional 2-chloro substitution was favorable for receptor selectivity. However, unlike the ribose forms, efficacy was reduced in N6-(3-iodobenzyl) analogues, such that partial A3 receptor agonists 7c and 9c were produced.

Partial agonists are possibly more desirable than full agonists as therapeutic agents due to potentially reduced side effects in the former. Partial agonists may display *in vivo* specificity for sites at which spare receptors are present, and the drug would therefore behave with apparent "full" efficacy. Thus, for compounds 7c and 9c, partial agonism combined with unprecedented functional potency at A3 receptors (<1 nM) may give rise to tissue selectivity.

Thus, at least three of the four adenosine receptors favor the N-conformation. For another member of the GPCR superfamily, the P2Y1 receptor, we recently reported that the ribose N-conformation of adenine nucleotides also appears to be preferred at the receptor binding site. Thus, the P1 and at least one of the P2 purinoceptors share the preference for the N-conformation. This may suggest a common motif of binding of nucleoside moieties among these GPCRS. The insights of this conformational preference may be utilized in simulated docking of adenosine agonists in a putative receptor binding site and to design even more potent and selective agents.

At the binding site of ADA, the N-isomer is also preferred, although the carbocyclic adenosine analogues are relatively poor substrates (relative rates of deamination are: 5a, 100; 5b, 0.99; 5c, 0.58; 5d, 0.010. N6-substituted analogues, such as 6c - 9c, would not be expected to be substrates for ADA. Other enzymes, such as HIV reverse transcriptase and Herpes thymidine kinase (HSV-1 TK) are also able to discriminate between the two antipodal conformations of restricted methanocarba thymidine analogues.

In conclusion, we have found that the introduction of a methano-carbocyclic modification of the ribose ring of purine

agonists represents a general approach for the enhancement of pharmacodynamic and because of the absence of the glycosyl bond, potentially of pharmacokinetic properties. This approach could therefore be applied to the development of  
5 cardioprotective, cerebroprotective, and anti-inflammatory agents.

## EXAMPLE 2

### Introduction

10 P2 receptors, which are activated by purine and/or pyrimidine nucleotides, consist of two families: G protein-coupled receptors termed P2Y, of which 5 mammalian subtypes have been cloned, and ligand-gated cation channels termed P2X, of which 7 mammalian subtypes have been cloned. The P2Y<sub>1</sub>  
15 receptor, which is present in the heart, skeletal and various smooth muscles, prostate, ovary, and brain, was the first P2 subtype to be cloned. The nomenclature of P2 receptors and their various ligand specificities is well established.

Nucleotide agonists binding at P2Y<sub>1</sub> receptors induce  
20 activation of phospholipase C (PLC), which generates inositol phosphates and diacylglycerol from phosphatidyl inositol-(4,5)-bisphosphate, leading to a rise in intracellular calcium. A P2Y<sub>1</sub> receptor antagonist may have potential as an anti-thrombotic agent, while a selective P2Y<sub>1</sub> receptor agonist  
25 may have potential as an anti-hypertensive or anti-diabetic agent.

Recently, progress in the synthesis of selective P2 receptor antagonists has occurred. Adenosine 3',5'- and 2',5'-bisphosphates were recently shown to be selective  
30 antagonists or partial agonists at P2Y<sub>1</sub> receptors, and other

classes of P2 antagonists include pyridoxal phosphate derivatives, isoquinolines, large aromatic sulfonates related to the trypanocidal drug suramin and various dyestuffs, and 2',3'-nitrophenylnucleotide derivatives. Synthesis of analogues of adenosine bisphosphates has resulted in N<sup>6</sup>-methyl-2'-deoxyadenosine-3',5'-bisphosphate (1a, MRS 2179), a competitive antagonist at human and turkey P2Y<sub>1</sub> receptors, with a KB value of approximately 100 Nm. The presence of an N<sup>6</sup>-methyl group and the absence of a 2'-hydroxyl group both enhanced affinity and decreased agonist efficacy, thus resulting in a pure antagonist at both turkey and human P2Y<sub>1</sub> receptor. The corresponding 2-C1 analogue (1b, MRS 2216) was slightly more potent than 1a as an antagonist at turkey P2Y<sub>1</sub> receptors, with an IC<sub>50</sub> value of 0.22 μM in blocking the effects of 10 nm 2-methylthioadenosine-5'diphosphate (2-MeSADP). MRS2179 (compound 1a) was inactive at P2Y<sub>2</sub>, P2Y<sub>4</sub>, and P2Y<sub>6</sub> subtypes, at the adenylyl cyclase-linked P2Y receptor in C6 glioma cells and at a novel avian P2Y receptor that inhibits adenylyl cyclase. However, the selectivity of this series of nucleotides for the P2Y<sub>1</sub> receptor is not absolute, since 1a also displayed considerable activity at P2X<sub>1</sub> receptors (EC<sub>50</sub> 1.2 μM), but not at P2Y<sub>2-4</sub> receptors.


In order to move away from the nucleotide structure of 1a and thereby increase biological stability and selectivity for the receptors in the present study, further structural modifications of the ribose moiety have been carried out. We have explored the SAR of these two series and introduced major modifications of the ribose moiety. These modifications include fixing the ring pucker conformation in the carbocyclic

series using a bridging cyclopropane ring, ring enlargement with introduction of a nitrogen atom, and ring contraction.

## Results


### Chemical synthesis

- 5        The methanocarbocyclic 2'-deoxyadenosine analogues in which the fused cyclopropane ring fixes the conformation of the carbocyclic nucleoside into a rigid northern or southern envelope conformation, as defined in the pseudorotational cycle, were synthesized as precursors of nucleotides 4 and 5
- 10    by the general approach of Marquez and coworkers. Again, the N<sup>6</sup>-methyl group was introduced by the Dimroth rearrangement, as shown below.



2-

- Position adenine modifications were further introduced in the
- 15    N-configuration series as shown below.



### Biological activity

Adenine nucleotides markedly stimulate inositol lipid hydrolysis by phospholipase C in turkey erythrocyte membranes, through activation of a P2Y<sub>1</sub> receptor. The agonist used in screening these analogues, 2-MeSADP, has a higher potency than the corresponding triphosphate for stimulation of inositol phosphate accumulation in membranes isolated from [<sup>3</sup>H]inositol-labeled turkey erythrocytes.

The deoxyadenosine bisphosphate nucleotide analogues prepared in the present study were tested separately for agonist and antagonist activity in the PLC assay at the P2Y<sub>1</sub> receptor in turkey erythrocyte membranes, and the results are reported in Table 3. Concentration-response curves were determined for each compound alone and in combination with 10nM 2-MeSADP.

Marquez and coworkers have introduced the concept of ring-constrained carbocyclic nucleoside analogues, based on cyclopentane rings constrained in the *N*-(Northern) and *S*-(Southern) conformations by fusion with a cyclopropane

(methanocarba) ring. In the presnet studies the series of ring-constrained *N*-methanocarba derivatives, the 6-NH<sub>2</sub> analogues, 4a was a pure agonist of EC<sub>50</sub> 152 nM and 88-fold more potent than the corresponding *S*-isomer, 5, also an agonist.

5. Thus, the ribose ring *N*-conformation appeared to be favored in recognition at P2Y<sub>1</sub> receptors. The N<sup>6</sup>-methy- and 2-chloro-N<sup>6</sup>-methyl-*N*-methanocarba analogues, 4b and 4c, were antagonists having IC<sub>50</sub> values of 276 and 53 nM, respectively.

#### 10 Molecular modeling.

- To better understand the role of the sugar puckering on the human P2Y<sub>1</sub> agonist and antagonists activities, we carried out a molecular modeling study of this new generation of ribose-modified ligands. Such modifications include
- 15 cyclopentyl rings constrained in the *N*- and *S*- conformations with cyclopropyl (methanocarba) groups, six-membered rings (morpholino and anhydrohexitol analogues), and cyclobutyl nucleotides. We have recently developed a model of the human P2Y<sub>1</sub> receptor, using rhodopsin as a template, by adapting a
- 20 facile method to simulate the reorganization of the native receptor structure induced by the ligand coordination (*cross-docking* procedure). Details of the model building are given in the Experimental Section. We have also reported the
- hypothetical molecular basis for recognition by human P2Y<sub>1</sub>
- 25 receptors of the natural ligand ATP and the new potent, competitive antagonist 2'-deoxy-N<sup>6</sup>-methyladenosine-3',5'-bisphosphate. Both ATP and 1a are present in the hypothetical binding site with a *N*-sugar ring conformation. In the present work, the sterically constrained *N*- and *S*-methanocarba agonist



analogues, 4a and 5, respectively, were docked into the putative binding site of our previously reported P2Y<sub>1</sub> receptor model. According to their structural similarity, the *cross-docking* procedure demonstrated that the receptor architecture found for binding the ATP and 1a was energetically appropriate also for the binding of both 4a and 5. However, *N*-methanocarba/ P2Y<sub>1</sub> complex appeared more stable by approximately 20 kcal/mol than *S*-methanocarba/P2Y<sub>1</sub> complex. In the lowest energy docked complex of *N*-methanocarba agonist in the proposed ligand binding cavity the side chain of Gln307 is within hydrogen bonding distance of the N<sup>6</sup> atom at 1.8Å, and the side chain of Ser314 is positioned at 2.0Å from the N<sup>1</sup> atom and at 3.4Å from the N<sup>6</sup> of the purine ring. As already reported, another three amino acids are important for the coordination of the phosphate groups in the antagonist: Arg128, Lys280 and Arg310. Lys280 may interact directly with both 3'-5'-phosphates (1.7Å, O3' and 1.7Å, O5'), whereas Arg128 and Arg310 are within ionic coupling range to both the O2 and O3 atoms of the 5'-phosphate. In molecular modeling studies poor superimposition (*rms*=1.447) between the *N*- and *S*-methanocarba agonist analogues has been found inside the receptor binding domain. In particular, the adenine moiety and 5' phosphate of the *S*-methanocarba derivative are shifted out position relative to with the *N*-methanocarba isomer, decreasing the stability of the *S*-methanocarba/PSY<sub>1</sub> complex. This fact might be correlated with the difference of their biological activity as seen in Table 4 below.

Using the information that a common binding site could be hypothesized among these deoxyadenosine bisphosphate analogues, a superimposition analysis of the energy-minimized

of the more potent antagonists has been performed. In this analysis we have used 1a as a reference compound, and we have defined three matching pairs of atoms, corresponding to N<sup>1</sup> atom of the purine ring and the P atoms of both 3' and 5' phosphate groups, to carry out the superimposition analysis. As reported in Table 4, acceptable RMS values have been obtained for all the antagonists compared with the 1a structure. As shown in Fig 4A, this superimposition study suggested that the two phosphate groups may occupy a common receptor regions, and a general pharmacophore model for bisphosphate antagonists binding to the human PSY<sub>1</sub> receptor can be extrapolated.

#### Discussion

In conclusion the present study has identified new pharmacological probes of PSY<sub>1</sub> receptors, including full agonists, partial agonists, and antagonists. The SAR of 1a indicates that the ribose ring oxygen may be readily substituted with carbon. Furthermore, analogues of constrained conformation, e.g. the methanocarpa analogues, display enhanced receptor affinity. Additional 2-chloro and N<sup>6</sup>-methyl substitution is favorable for affinity at PSY<sub>1</sub> receptors, and nearly pure antagonism is maintained provided that the N<sup>6</sup>-methyl group is present.

Thus, the biological potency and efficacy of this series of bisphosphates appears to be highly dependent on subtle conformational factors, which would influence the orientation of the phosphate groups within the receptor binding site.

The sugar moiety of nucleosides and nucleotides in solution is known to exist in a rapid, dynamic equilibrium

between extreme 2-*exo*/3'-*endo* (*N*-) and 2'-*endo*/3'-*exo* (*S*-) conformations as defined in the pseudorotational cycle. While the energy gap between *N*- and *S*-conformation is in the neighborhood of 4kcal/mol, such a disparity can explain the difference between micromolar and nanomolar binding affinities. Using a molecular modeling approach, we have analyzed the sugar conformational requirements for a new class of bisphosphate ligands binding to the human PSY<sub>1</sub> receptor. As experimentally shown, the ribose ring Northern conformation appeared to be favored in recognition at human PSY<sub>1</sub> receptor (see Table 4). We have found new support to our recently presented hypothesis in which three important recognition regions are present in the bisphosphate molecular structures; The N<sup>1</sup> atom of the purine ring and the P atoms of both 3' and 5' phosphate groups. The *N*-conformation seems to be essential to maximize the electrostatic interactions between the negatively charged phosphates and the positively charged amino acids present in the receptor binding cleft, as well Arg128, Lys280, and Arg310.

Interestingly, the electrostatic contacts also appear to be crucial for the recognition of bisphosphate antagonists. Using superimposition analysis, a general pharmacophore model for the bisphosphate antagonists binding to the PSY<sub>1</sub> receptor has been proposed. According to the pharmacophore map, recognition of the bisphosphates antagonists at a common region inside the receptor binding site and, consequently, a common electrostatic potential profile is possible. As well for the agonists, the Northern conformation seems to be essential to maximize the electrostatic interactions between the negatively charged phosphates and the positively charged

amino acids presents in the receptor binding cleft. As we predicted using the previously reported PSY<sub>1</sub> receptor model, sugar moiety does not seem to be crucial for the ligand recognition process.

5 As already described, the simple addition of the N<sup>6</sup>-methyl group in several cases converted pure agonists to antagonists. From a pharmacological point of view, this is really a unique situation. With the addition of the N<sup>6</sup>-methyl group it is not possible to have a double hydrogen-bonding  
10 interaction and, consequently, the activation pathway is blocked. However, for all the N<sup>6</sup>-methyl antagonists the possibility to participate in at least one of the two possible hydrogen bonds appears to be very important for the increase in affinity at the PSY<sub>1</sub> receptor.

15

#### Chemical Synthesis

Nucleosides and synthetic reagents were purchased from Sigma Chemical Co. (St. Louis, MO) and Aldrich (St. Louis, MO). 6-Chloro-2'-deoxypurine riboside was obtained from  
20 Sigma. Several 2'-deoxynucleosides, including an anhydrohexitol-adenine nucleoside and 2'-deoxyaristeromycin were also synthesized.

Purity of compounds was checked using a Hewlett-Packard 1090 HPLC apparatus equipped with an SMT OD-5-60 RP-C18  
25 analytical column (250 x 4.6 mm; Separation Methods Technologies, Inc., Newark, DE) in two solvent systems. System A: Linear gradient solvent system: 0.1 M TEAA/CH<sub>3</sub>CN from 95/5 to 40/60 in 20 min and the flow rate was of 1 mL/min. System B: linear gradient solvent system: 5 mM  
30 TBAP/CH<sub>3</sub>CN from 80/20 to 40/60 in 20 min and the flow rate was

of 1 mL/min. Peaks were detected by UV absorption using a diode array detector. All derivatives showed more than 95% purity in the HPLC systems.

Purification of most of the nucleotide analogues for biological testing was carried out on DEAE-A25 Sephadex columns as described above. However, compounds 7b and 8a - c required HPLC purification (system a, semi-preparative C18 column) of the reaction mixtures.

**General procedure of phosphorylation.**

10 **Method A:** The nucleoside (0.1 mmol) and Proton Sponge® (107 mg, 0.5 mmol) were dried for several h in high vacuum at room temperature and then suspended in 2 mL of trimethyl phosphate. Phosphorous oxychloride (Aldrich, 37  $\mu$ L, 0.4 mmol) was added, and the mixture was stirred for 1 h at 0° C. The reaction was  
15 monitored by analytical HPLC (eluting with a gradient consisting of buffer: CH<sub>3</sub>CN in the ratio 95 : 5 to 40 : 60, in which the buffer was 0.1 M triethylammonium acetate (TEAA); elution time was 20 min; flow rate was 1 mL/min; column was SMT OD -5-60 RP-C18; detector was by UV in the E<sub>max</sub> range of  
20 260-300 nm). The reaction was quenched by adding 2 mL of triethylammonium bicarbonate buffer and 3 mL of water. The mixture was subsequently frozen and lyophilized. Purification was performed on an ion-exchange column packed with Sephadex-  
25 DEAE A-25 resin, a linear gradient (0.01 to 0.5 M) of 0.5 M ammonium bicarbonate was applied as the mobile phase, and UV and HPLC were used to monitor the elution. All nucleotide bisphosphates were collected, frozen and lyophilized as the ammonium salts. All synthesized compounds gave correct molecular mass (high resolution FAB) and showed more than 95%  
30 purity (HPLC, retention times are reported in Table 4).

- Method B: Nucleoside (0.1 mmol) dried for several h in high vacuum at room temperature was dissolved in 2 mL of dry THF. Lithium diisopropylamide solution (Aldrich, 2.0 M in THF, 0.4 mmol) was added slowly at -78 °C. After 15 min tetrabenzyl pyrophosphate (Aldrich, 0.4 mmol) was added and the mixture was stirred for 30-60 min at -78°C. The reaction mixture was warmed to 0°C - rt and stirred for an addition period ranging from 2h to 24 h. Chromatographic purification (pTLC, CHCl<sub>3</sub>:CH<sub>3</sub>OH(10:1) gave the tetrabenzyl phosphorylated compound. This compound (20 mg) was dissolved in a mixture of methanol (2 mL) and water (1 mL) and hydrogenated over a 10 % Pd-on-C catalyst (10 mg) at rt for 62 h. The catalyst was removed by filtration and the methanol was evaporated. The residue was treated with ammonium bicarbonate solution and subsequently frozen and lyophilized. Purification, if necessary, was by the same procedure as in method A.
- (*N*-Methanocarpa-2'-deoxyadenosine-3',5'-bis(diammonium phosphate) (4a) [(1R,2S,4S,5S)-1-[(phosphato)methyl]-4-(6-aminopurin-9-yl) bicyclo [3.1.0.] -hexane-2-phosphate tetraammonium salt]
- Starting from 16 mg (0.06 mmol) of (*N*)-methanocarpa-2'-deoxyadenosine and following the general phosphorylation procedure A we obtained 1.8 mg (0.0037 mmol, 5.5 % yield) of the desired compound.
- <sup>1</sup>H-NMR (D<sub>2</sub>O) δ 0.90 (1H, m, CH<sub>2</sub>-6), 1.10 (1H, m, CH<sub>2</sub>6'), 1.82 (1H, m, CH-5), 1.91 (1H, m, CH<sub>2</sub>-3') 2.23 (1H, m, CH<sub>2</sub>-3'), 3.49 (1H, d, J = 11.7 Hz, CH<sub>2</sub>-OH), 4.16 (1H, d, J = 6.9 Hz, CH<sub>2</sub>-2'), 8.39 (1H, s, H-2), 8.54 (1H, s, H-8).
- <sup>31</sup>P-NMR (D<sub>2</sub>O) δ 0.43 (s, 5'P); -0.19 (s, 3'P).

(N)-Methanocarba-N<sup>6</sup>-methyl-2'-deoxyadenosine-3',5'-  
bis(diammonium phosphate) (4b)

(1R,2S,4S,5S)-1-[(phosphato)methyl]-4-(6-methylaminopurin-9-  
yl) bicyclo [3.1.0]-hexane-2-phosphate tetraammonium salt]

5 13.5 mg (0.0170 mmol) of compound 18 was converted to the  
corresponding phosphoric acid analog using hydrogenation  
following the general procedure B. Purification was performed  
on an ion-exchange column packed with Sephadex-DEAE A-25  
resin, linear gradient (0.01 to 0.5 M) of 0.5 M ammonium  
10 bicarbonate was applied as the eluant to give 3.0 mg (0.0060  
mmol, 35.3 % yield) of the desired compound.

<sup>1</sup>H-NMR (D<sub>2</sub>O) δ 0.93-0.98 (1H, m, CH<sub>2</sub>-6'), 1.17 (1H, m, CH<sub>2</sub>-6'),  
1.86-1.88 (1H, m, CH<sub>5</sub>'), 1.94-1.98 (1H, m, CH<sub>2</sub>-3'), 2.23-2.31  
(1H, m, CH<sub>2</sub>-3'), 3.09 (3H, bs, N<sup>6</sup>-CH<sub>3</sub>), 3.61-3.64 (1H, m,  
15 CH<sub>2</sub>OH), 4.51-4.55 (1H, m, CH<sub>2</sub>OH), 5.01-5.03 (1H, m, CH-4'),  
5.19-5.21 (1H, m, CH-2'), 8.22 (1H, s, H-2), 8.51 (1H, s, H-  
8). <sup>31</sup>P-NMR (D<sub>2</sub>O) δ 1.26, 1.92 (2s, 3'-P, 5'-P).

(N)-Methanocarba-N<sup>6</sup>-methyl-2-chloro-2'-deoxyadenosine-3',5'-  
bis(diammonium phosphate) (4c)

20 [(1R,2S,4S,5S)-1[(phosphato)methyl]-4-(2-chloro-6-aminopurin-  
9-yl) bicyclo [3.1.0]-hexane-2-phosphate tetraammonium salt]

The nucleoside, compound 23, reacted with tetrabenzyl  
pyrophosphate, as in Method B, followed by an alternative  
deprotection procedure. Starting from 10 mg (0.0323 mmol) of  
25 (N)-methanocarba-N<sup>6</sup>-methyl-2-chloro-2'-deoxyadenosine and  
following the general phosphorylation procedure (Method B) we  
obtained 9.5 mg (0.0114 mmol, 35.3 % yield) of the desired

compound, (N)-methanocarba-N<sup>6</sup>-methyl-2-chloro-2'-deoxyadenosine-3',5'-bis(dibenzyl phosphate).

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ 0.75-0.81 (H, m, CH<sub>2</sub>-6'), 1.03-1.08 (1H, m, CH<sub>2</sub>-6'), 1.49-1.51 (1H, m, CH-5'), 1.84-1.94 (1H, m, CH<sub>2</sub>-3'), 1.99-2.10 (1H, m, CH<sub>2</sub>-3'), 3.12 (3H, bs, N<sup>6</sup>-CH<sub>3</sub>), 4.11-4.20 (1H, m, CH<sub>2</sub>OH), 4.50-4.55 (H, m, CH<sub>2</sub>OH), 4.90-4.98, (8H, m, -OCH<sub>2</sub>), 4.99-5.01 (1H, m, CH-4'), 5.23-5.30 (1H, m, CH-2'), 5.90 (1H, bs, NH), 7.20-7.29 (20H, m, C<sub>6</sub>H<sub>5</sub>), 7.82 (1H, s, H-8)

<sup>31</sup>P-NMR (D<sub>2</sub>O) δ -0.58 (s, 5'-P); -1.06 (s, 3'-P).

10 MS(CI-NH<sub>3</sub>) (M+1) 830 HRMS (FAB-) (M+Cs) Calcd. 962.1252; Found 962, 1252

9.5 mg (0.0114 mmol) of the tetrabenzyl-protected intermediate added to dry CH<sub>2</sub>Cl<sub>2</sub> (1.0 mL) was cooled to -78 °C under argon and treated with 100 µL of boron trichloride solution (1M in CH<sub>2</sub>Cl<sub>2</sub>) and 100 µL of anisole. The reaction mixture was stirred for 12 hr at 0 °C to rt and extracted with triethylamine solution. Purification was performed on an ion-exchange column packed with Sephadex-DEAE A-25 resin, linear gradient (0.01 to 0.5 M) of 0.5 M ammonium bicarbonate was applied as the eluent to give 0.4 mg (0.0007 mmol, 6.52 yield) of the desired compound 4c.

<sup>1</sup>H-NMR (D<sub>2</sub>O) δ 0.91-0.96 (1H, m, CH<sub>2</sub>-6'), 1.12-1.16 (1H, m, CH<sub>2</sub>-6'), 1.80-1.84 (1H, m, CH-5'), 1.85-1.98 (1H, m, CH<sub>2</sub>-3'), 2.20-2.50 (1H, m, CH<sub>2</sub>-3'), 3.08 (3H, bs, N<sup>6</sup>-CH<sub>3</sub>), 3.57-3.60 (1H, m, CH<sub>2</sub>OH), 4.52-4.67 (1H, m, CH<sub>2</sub>OH), 4.94-4.96 (1H, m, CH-4'), 5.18-5.21 (1H, m, CH-2'), 8.52 (1H, s, H-8)

<sup>31</sup>P-NMR (D<sub>2</sub>O) δ 1.82, 2.52 (2s, 3'-P, 5'-P)



(S)-Methanocarba-2', deoxyadenosine-3',5'-bis(diammonium phosphate (5) [(1S,3S,4R,5S)-4-[(phosphato)methyl]-1-(6-aminopurin-9-yl) bicyclo [3.1.0]-hexane-3-phosphate tetraammonium salt]

5 Starting from 16 mg (0.06 mmol) of (S)-methanocarba-2'-deoxyadenosine and following the general phosphorylation procedure A, we obtained 2.1 mg (0.0043 mmol, 7.55 yield) of the desired compound 5.

<sup>1</sup>H-NMR (D<sub>2</sub>O) δ 1.36 (1H, m, CH<sub>2</sub>-6'), 1.53 (1H, t, J = 4.8 Hz, CH<sub>2</sub>-6'), 2.05 (1H, m, CH<sub>2</sub>-5'), 2.30 (1H, m, CH-4'), 2.46 (2H, m, CH<sub>2</sub>-2'), 3.97 (2H, m, CH<sub>2</sub>OH), 4.45 (1H, d, J = 6.6 Hz, CH-3'), 8.16 (1H, s, H-2), 8.30 (1H, s, H-8). <sup>31</sup>P-NMR (D<sub>2</sub>O) δ 0.85 (bs, 5'P); 0.31 (bs, 3'P).

15 [(1S,3S,4R,5S)-1-[(Hydroxy)methyl]-2-hydroxy-4-(6-methylaminopurin-9-yl) bicyclo [3.1.0]-hexane (17b)

The Dimroth rearrangement (Scheme 2) was carried out on (N)-methanocarba-2'-deoxyadenosine. Specifically, the (N)-methanocarba-2'-deoxyadenosine (17a, 50.0 mg, 0.191 mmol) was heated at 40° C with methyl iodide (71.5 μL, 1.15 mmol) in dry DMF (2.0 mL) for 48 h. The solvent was evaporated under reduced pressure, and the residue was heated at 90 °C with ammonium hydroxide (4.0 mL) for 4 h. The water was evaporated, and the residue was purified by pTLC using MeOH; CHCl<sub>3</sub> (1:9) to afford compound 17b as a colorless solid (40 mg, 0.15 mmol, 76%).

<sup>1</sup>H-NMR (CD<sub>3</sub>OD) δ 0.77.-0.81 (1H, m, CH<sub>2</sub>-6'), 1.03-1.07 (1H, m, CH<sub>2</sub>-6'), 1.68-1.72 (1H, m, CH-5'), 1.79-1.89 (1H, m, CH<sub>2</sub>-3'), 2.00-2.07 (1H, m, CH<sub>2</sub>-3'), 3.12 (3H, bs, N<sup>6</sup>-CH<sub>3</sub>), 3.33 (1H, d, J = CH<sub>2</sub>OH), 4.29 (1H, d, J = 11.7 Hz, CH<sub>2</sub>OH), 4.89-4.92 (1H, m,

CH-4'), 5.02 (1H, d,  $J = 6.9$  Hz, CH-2'), 8.24 (1H, s, H-2), 8.49 (1H, s, H-8).

MS(CI-NH<sub>3</sub>) : 276 (M+1) 830 HRMS(FAB-) (M+Cs) Calcd. 275.1382; Found 275.1389.

5 (N)-Methanocarba-N<sup>6</sup>-methyl-2'-deoxyadenosine-3',5'-

bis(dibenzylphosphate) (18)

[(1S,2S,4Z,5S)-1-[(dibenzylphosphato)methyl]-4-(6-methylaminopurin-9-yl) bicyclo [3.1.0]-hexane-2-dibenzylphosphate]

10 Starting from 20.0 mg (0.0726 mmol) of N-methanocarba-N<sup>6</sup>-methyl-2'-deoxyadenosine 17b and following the general phosphorylation procedure (Method B we obtained 13.5 mg (0.0170 mmol, 23.4 % yield) of the desired protected intermediate, 18 as shown in Scheme 2.

15 <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$  0.73-0.78 (1H, m, CH<sub>2</sub>-6'), 0.94-.0.98 (1H, m, CH<sub>2</sub>-6'), 1.53-1.54 (1H, m, CH-5'), 1.81-1.91 (1H, m, CH<sub>2</sub>-3'), 2.05-2.13 (1H, m, CH<sub>2</sub>-3'), 3.15 (3H, bs, N<sup>6</sup>-CH<sub>3</sub>), 3.70-3.83 (1H, m, CH<sub>2</sub>OP), 4.49-4.55 (1H, m, CH<sub>2</sub>OP), 4.89-5.00 (8H, m, OCH-2), 5.02-5.06 (1H, m, CH-4'), 5.27-5.32 (1H, m, CH-2'),  
20 5.86 (1H, bs, NH), 7.21-7.23 (20H, m, C<sub>6</sub>H<sub>5</sub>), 7.86 (1H, s, H-2), 8.31 (1H, s, H-8). <sup>31</sup>P-NMR (D<sub>2</sub>O)  $\delta$  -0.56, -1.05 (2s, 3'-P, 5'-P)  
HRMS (FAB-) (M-Cs) Calcd. 928.1641; Found 928.1700.

[(1S,2S,4Z,5S)-1-[(Benzyloxy)methyl]-2-benzyloxy-4-(2-6-dichloropurin-9-yl) bicyclo [3.1.0]-hexane (21)

25 To an ice cold solution of triphenylphosphine (278 mg, 1.06 mmol) in dry THF (2 mL) was added diethylazadicarboxylate (170  $\mu$ L, 1.06 mmol) dropwise under a nitrogen atmosphere, and the mixture was stirred for 20 min until the solution turned red orange (Scheme 3). This mixture was added dropwise to a cold

stirred mixture of the starting alcohol (135 mg, 0.417 mmol) and 2,6-dichloropurine (157 mg, 0.883 mmol) under a nitrogen atmosphere. The reaction mixture was stirred in an ice bath for 30 min and then allowed to warm to room temperature, and stirring continued for 12 h. Solvent was removed by nitrogen purge, and the residue was purified by pTLC using EtOAc : petroleum ether (1 : 1) to afford a thick liquid (132 mg, 0.263 mmol, 64%).

<sup>1</sup>H NMR: (CD<sub>3</sub>OD) δ 0.85 (m, 1H), 1.13 (m, 1H), 1.59 (m, 1H), 1.68 (m, 1H), 2.06 (m, 1H), 3.17 (d, J = 10.8 Hz, 1H), 4.11-4.57 (m, 5H), 5.20 (d, J = 6.9 Hz, 1H), 6.6 (bs, 1H), 7.23-7.37 (m, 10H), 8.98 (s, 1H).

MS : (EI) 494 (M+).

[(1*R*,2*S*,4*S*,5*S*)-1-[(Benzyloxy)methyl]-2-benzyloxy-4-(2-chloro-6-methylaminopurin-9-yl) bicyclo [3.1.0]-hexane (22)

Compound 21 (100 mg, 0.202 mmol) was dissolved in methylamine in methanol (30 % solution, 3mL) and was stirred at rt for 12 h under a nitrogen atmosphere. The solvent was evaporated, and the crude product was purified by pTLC using EtOAc : petroleum ether (6 : 4) to afford 22 as a light yellow solid (86 mg, 0.176 mmol, 88 %).

<sup>1</sup>H NMR: (CD<sub>3</sub>OD) δ 0.70 (m, 1H), 1.06 (m, 1H), 1.50 (m, 1H), 1.76 (m, 1H), 1.96 (m, 1H), 3.01 (s, 3H), 3.08 (m, 2H), 4.03 (m, 4H), 4.45 (bs, 1H), 5.02 (bs, 1H), 8.38 (s, 1H).

MS : (CI) : 490 (M+1).

[(1*R*,2*S*,4*S*,5*S*)-1-[(Hydroxy)methyl]-2-hydroxy-4-(2-chloro-6-methylaminopurin-9-yl) bicyclo [3.1.0]-hexane (23)

Compound 22 (40 mg 0.0816 mmol) was dissolved in dry CH<sub>2</sub>Cl<sub>2</sub> (1.0 mL), and hydrogenated using BCl<sub>3</sub> (1M in CH<sub>2</sub>Cl<sub>2</sub>, 175 μL) for 50 min at -78 °C under argon. The solvent was evaporated,

and the crude product was purified by pTLC using  $\text{CHCl}_3$  : MeOH (10 : 1) to afford 23 as a light yellow solid (10.0 mg, 0.0323 mmol, 39.6 %).

$^1\text{H}$  NMR: ( $\text{CD}_3\text{OD}$ )  $\delta$  0.77-0.81 (1H, m,  $\text{CH}_2\text{-6'}$ ), 1.02-1.05 (1H, m,  $\text{CH}_2\text{-6'}$ ), 1.65-1.68 (1H, m,  $\text{CH-5'}$ ), 1.78-1.91 (1H, m,  $\text{CH}_2\text{-3'}$ ), 1.99-2.07 (1H, m,  $\text{CH}_2\text{-3'}$ ), 3.08 (3H, bs,  $\text{N}^6\text{-CH}_3$ ), 3.37 (1H, d,  $J = 11.7$  Hz,  $\text{CH}_2\text{OH}$ ), 4.27 (1H, d,  $J = 11.7$  Hz,  $\text{CH}_2\text{OH}$ ), 4.89-4.91 (1H, m,  $\text{CH-4}$ ), 4.97 (1H, d,  $J = 6.8$  Hz,  $\text{CH-2'}$ ), 8.46 (1H, s, H-8).

MS : ( $\text{CI-NH}_3$ ): 310 ( $\text{M}+1$ ), HRMS (FAB-): Calcd 309.0992, Found 309.0991.

#### Pharmacological Analyses.

$\text{P2Y}_1$  receptor promoted stimulation of inositol phosphate formation by adenine nucleotide analogues was measured in turkey erythrocyte membranes as previously described. The  $\text{K}_{0.5}$  values were averaged from 3-8 independently determined concentration-effect curves for each compound. Briefly, 1 mL of washed turkey erythrocytes was incubated in inositol-free medium (DMEM; Gibco, Gaithersburg MD) with 0.5 mCi of 2- $[\text{^3H}]$ myo-inositol (20Ci/mmol: American Radiolabelled Chemicals, Inc., St. Louis MO) for 18-24 h in a humidified atmosphere of 95% air/5%  $\text{CO}_2$  at 37 °C. Erythrocyte ghosts were prepared by rapid lysis in hypotonic buffer (5 mM sodium phosphate, pH 7.4, 5 mM  $\text{MgCl}_2$ , 1mM EGTA) as described. Phospholipase C activity was measured in 25  $\mu\text{L}$  of  $[\text{^3H}]$  inositol-labeled ghosts (approximately 175  $\mu\text{g}$  of protein, 200-500,000 cpm/assay) in a medium containing 424  $\mu\text{M}$   $\text{CaCl}_2$ , 0.91 mM  $\text{MgSO}_4$ , 2mM EGTA, 115 mM KCl, 5 mM  $\text{KH}_2\text{PO}_4$ , and 10 mM Hepes pH 7.0. Assays (200  $\mu\text{L}$

final volume) contained 1  $\mu$ M GTP $\gamma$ S and the indicated concentrations of nucleotide analogues. Ghosts were incubated at 30 °C for 5 min, and total [ $^3$ H]inositol phosphates were quantitated by anion exchange chromatography as previously  
5 described.<sup>7,36</sup>

#### Data analysis.

Agonist potencies were calculated using a four-parameter logistic equation and the GraphPad software package (GraphPad, San Diego, CA). EC<sub>50</sub> values (mean  $\pm$  standard error) represent  
10 the concentration at which 50 % of the maximal effect is achieved. Relative efficacy (%) was determined by comparison with the effect produced by a maximal effective concentration of 2-MeSADP in the same experiment.

Antagonist IC<sub>50</sub> values (mean  $\pm$  standard error) represent  
15 the concentration needed to inhibit by 50 % the effect elicited by 10 nM 2-MeSADP. The percent of maximal inhibition is equal to 100 minus the residual fraction of stimulation at the highest antagonist concentration.

All concentration-effect curves were repeated in at least  
20 three separate experiments carried out with different membrane preparations using duplicate or triplicate assays.

Table 3

Stimulation of PLC at turkey erythrocyte P2Y<sub>1</sub> receptors (agonist effect) and the inhibition of PLC stimulation elicited by 10 nM 2-MeSADP (antagonist effect), for at least two separate determinations.

Compound	Agonist Effect, % of maximal increase <sup>a</sup>	EC <sub>50</sub> , $\mu$ M <sup>a</sup>	Antagonist Effect, % of maximal inhibition <sup>b</sup>	IC <sub>50</sub> , $\mu$ M <sup>b</sup> (n)
1a <sup>c,e</sup> (MRS 2179)	NE		99 $\pm$ 1	0.331 $\pm$ 0.059 (5)
1b <sup>e</sup>	NE		95 $\pm$ 1	0.206 $\pm$ 0.053
1c <sup>e</sup>	4	d	96 $\pm$ 2	1.85 $\pm$ 0.74
1d <sup>e</sup>	6 $\pm$ 2	d	94 $\pm$ 2	0.362 $\pm$ 0.119
4a	92 $\pm$ 5	0.155 $\pm$ 0.021	NE	
4b	NE		100	0.157 $\pm$ 0.060
4c	NE		100	0.0516 $\pm$ 0.0008
5	41 $\pm$ 13	13.3	34% at 100 $\mu$ M	small decrease

- <sup>a</sup> Agonist potencies were calculated using a four-parameter logistic equation and the GraphPad software package (GraphPad, San Diego, CA). EC<sub>50</sub> values (mean  $\pm$  standard error) represent the concentration at which 50% of the maximal effect is achieved. Relative efficacies (%) were determined by comparison with the effect produced by a maximal effective concentration of 2-MeSADP in the same experiment. Small increase refers to <10% at 100  $\mu$ M.
- <sup>b</sup> Antagonist IC<sub>50</sub> values (mean  $\pm$  standard error) represent the concentration needed to inhibit by 50% the effect elicited by 10 nM 2-MeSADP. The percent of maximal inhibition is equal to 100 minus the residual fraction of stimulation at the highest antagonist concentration.
- <sup>c</sup> 1a, MRS 2179; 4c, MRS 2279.
- <sup>d</sup> EC<sub>50</sub> was not calculated for increases of 10% at 100  $\mu$ M.
- <sup>e</sup> values from refs. 17, 19.
- NE no effect at 100  $\mu$ M.

TABLE 4

Synthetic data for nucleotide derivatives, including structural verification using high resolution mass spectroscopy and purity verification using HPLC.

No	Formula	FAB (M-H <sup>+</sup> )		HPLC (rt; min) <sup>a</sup>		Method, Yield (%) <sup>b</sup>
		Calcd	Found	System A	System B	
2	C <sub>10</sub> H <sub>15</sub> O <sub>9</sub> N <sub>5</sub> P <sub>2</sub>	410.0267	410.0269	3.53	10.72	B, 21.7
3b	C <sub>12</sub> H <sub>19</sub> O <sub>8</sub> N <sub>5</sub> P <sub>2</sub>	422.0631	422.0664	3.41	8.21	B, 8.0
4a	C <sub>12</sub> H <sub>17</sub> O <sub>8</sub> N <sub>5</sub> P <sub>2</sub>	420.0474	420.0482	3.92	7.30	A, 5.5
4b	C <sub>13</sub> H <sub>19</sub> O <sub>8</sub> N <sub>5</sub> P <sub>2</sub>	434.0631	434.0622	5.91	7.83	B, 8.3
4c	C <sub>13</sub> H <sub>18</sub> O <sub>8</sub> N <sub>5</sub> P <sub>2</sub> Cl	468.0241	468.0239	8.05	8.54	B, 2.3
5	C <sub>12</sub> H <sub>17</sub> O <sub>8</sub> N <sub>5</sub> P <sub>2</sub>	420.0474	420.0481	4.02	6.84	A, 7.5
6	C <sub>11</sub> H <sub>16</sub> O <sub>8</sub> N <sub>5</sub> P <sub>2</sub> Cl	442.0084	442.0070	6.67	6.82	A, 24.3
7b	C <sub>12</sub> H <sub>20</sub> O <sub>12</sub> N <sub>5</sub> P <sub>3</sub>	518.0237	518.0243	4.98	12.74	A, 1.8
7c	C <sub>12</sub> H <sub>19</sub> O <sub>9</sub> N <sub>5</sub> P <sub>2</sub>	438.0580	438.0580	4.63	9.36	B, 50.1
7d	C <sub>12</sub> H <sub>18</sub> O <sub>9</sub> N <sub>5</sub> P <sub>2</sub> Cl	472.0201	472.0190	5.67	9.97	B, 31.3
8a	C <sub>12</sub> H <sub>20</sub> O <sub>8</sub> N <sub>6</sub> P <sub>2</sub>	437.0740	437.0721	2.37	8.78	8.0
8b	C <sub>12</sub> H <sub>21</sub> O <sub>11</sub> N <sub>6</sub> P <sub>3</sub>	517.0403	517.0404	2.42	9.23	7.2
8c	C <sub>12</sub> H <sub>22</sub> O <sub>14</sub> N <sub>6</sub> P <sub>4</sub>	597.0066	597.0053	2.96	10.02	4.0

<sup>a</sup> Purity of each derivative was 95%, as determined using HPLC with two different mobile phases. System A: gradient of 0.1M TEAA/CH<sub>3</sub>CN from 95/5 to 40/60 and System B: gradient of 5mM TEAP/ CH<sub>3</sub>CN from 80/20 to 40/60.

<sup>b</sup> Phosphorylation methods: Method A refers to use of phosphorous oxychloride, and Method B refers to use of tetrabenzyl pyrophosphate/lithium diisopropylamide followed by hydrogenation. The percent yields refer to overall yield for each phosphorylation sequence. For the method of synthesis of 8 refer to Experimental Section.

## 20 Abbreviations

AIBN, 2,2' -azobisisobutyronitrile;  
ATP, adenosine 5'-triphosphate;  
DBU, 1,8-diazabicyclo[5.4.0]undec-7-ene;

- DCTIDS, 1,3-dichlorotetraaisopropyl-1,1,3,3,-disiloxane;  
DEAD, diethylazadicarboxylate;  
DEAE, diethylaminoethyl;  
DMAP, 4-dimethylaminopyridine;  
5 DMF, dimethylformamide;  
DMSO, dimethylsulfoxide;  
FAB, fast atom bombardment (mass spectroscopy);  
HPLC, high pressure liquid chromatography;  
MS, mass spectroscopy;  
10 HRMS, high resolution mass spectroscopy;  
LDA, lithium diisopropylamide;  
2-MeSADP, 2-methylthioadenosine-5'-diphosphate;  
TBAP, tetrabutylammonium phosphate;  
TEAA, triethylammonium acetate;  
15 THF, tetrahydrofuran;

All of the references cited herein, including patents, patent applications, and publications, are hereby incorporated in their entireties by reference.


- While this invention has been described with an emphasis  
20 upon preferred embodiments, it will be obvious to those of ordinary skill in the art that variations of the preferred embodiments may be used and that it is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all  
25 modifications encompassed within the spirit and scope of the invention as defined by the following claims.



## WHAT IS CLAIMED IS:

1. A compound having the formula A-M, wherein A is a chemically modified adenine or uracil and M is a constrained cycloalkyl group, said adenine or uracil is bonded to said  
5 constrained cycloalkyl group, and said compound binds a receptor; or a salt of said compound.
2. The compound of claim 1, wherein said receptor is a P1 or P2 receptor.
- 10 3. The compound of claim 2, wherein said P1 receptor is selected from the group consisting of A<sub>1</sub>, A<sub>2A</sub>, and A<sub>3</sub>.
4. The compound of claim 2, wherein said P2 receptor is selected from the group consisting of P2Y and P2X.
5. The compound of claim 1, wherein said constrained  
15 cycloalkyl group includes a cyclopentyl group.
6. The compound of claim 3, wherein said constrained cyclopentyl group is a cyclopentyl ring derivatized with a fused cyclopropane bridge.
7. The compound of claim 1, wherein said constrained  
20 cycloalkyl group is constrained in the N- conformation.
8. The compound of claim 1, wherein said constrained cycloalkyl group is constrained in the S- conformation.

9. A compound selected from the group consisting of



wherein

$R_1$  is hydrogen, alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl,  
 5 arylalkyl, acyl, sulfonyl, arylsulfonyl, thiazolyl or  
 bicyclic alkyl;

$R_2$  is hydrogen, halo, alkyl, aryl, arylamino, aryloxyde,  
 alkynyl, alkenyl, thiol, cyano, or ;

$R_3$ ,  $R_4$ , and  $R_5$ , are each independently hydrogen, hydroxyl,  
 10 alkoxy, alkyl, alkenyl, alkynyl, aryl, acyl, alkylamino,  
 arylamino, phosphoryl, diphosphoryl, triphosphoryl,  
 phosphonyl, boronyl, thiophosphoryl, thiodiphosphoryl,  
 thiotriphosphoryl or vanadyl, and can be the same or  
 different;

15  $R_6$  is hydrogen, alkyl, alkenyl, alkynyl, heteroaryl or  
 aminoalkyl;

$R_7$  is methylene, dihalomethyl, carbonyl, sulfoxide;  
 and at least one of  $R_1$ ,  $R_2$ , and  $R_6$  is other than hydrogen;

$R_8$  is carbon or nitrogen;

20 or a salt of said compound.

10. The compound of claim 9, wherein  $R_1$  is alkyl, cycloalkyl, alkoxy, aryl, arylalkyl, bicycloalkyl, or sulfonyl.

11. The compound of claim 9, wherein  $R_1$  is methyl, cyclopentyl, cyclohexyl, phenyl, R-phenylisopropyl, benzyl, or phenylethyl;

$R_2$  is chloro;

and  $R_6$  is  $C_1$ - $C_6$  alkylamino,  $C_1$ - $C_6$  alkyl,  $C_2$ - $C_6$  alkenyl,  $C_2$ - $C_6$  alkynyl.

12. The compound of claim 9 or 10, wherein  $R_1$  is further substituted with a member selected from the group consisting of hydroxyl, halo, sulfonyl, amino, cyano, alkoxy, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, sulfonamido, carboxyl, and carboxamido.

13. The compound of claim 9, wherein  $R_1$  is methyl group and  $R_2$  is chloro, alkylthio, or arylalkylthio.


14. The compound of claim 9, wherein  $R_6$  is methyl and  $R_2$  is chloro, alkylthio, arylalkylthio or hydrogen.

15. The compound of claim 9, wherein  $R_6$  is halo and  $R_2$  is a chloro, alkylthio, arylalkylthio or hydrogen.

16. The compound of claim 9, wherein  $R_2$  is chloro.


17. The compound of claim 9, wherein  $R_1$  is methyl and  $R_2$  is chloro and  $R_3$  is hydrogen.

18. The compound of claim 9, wherein the compound has the formula




5 wherein  $\text{R}_1$  is iodobenzyl, or cyclopentyl and  $\text{R}_2$  is hydrogen or chloro.


19. The compound of claim 9, wherein the compound has the formula




20. The compound of claim 9, wherein the compound has the formula



21. A compound selected from the group consisting of:



61



wherein

$R_1$ ,  $R_2$ ,  $R_3$  is hydrogen, alkyl, alkenyl, alkynyl, aminoalkyl and  
 $R_3$ ,  $R_4$ , and  $R_5$ , are each independently hydrogen, hydroxyl,  
 5 alkoxy, alkyl, alkenyl, alkynyl, aryl, acyl, alkylamino,  
 arylamino, phosphoryl, phosphonyl, boronyl, or vanadyl, and  
 can be the same or different;

$R_6$  and  $R_7$  are each independently sulfur or oxygen;

and  $R_{10}$  is methylene, dihalomethyl, carbonyl, sulfoxide;

10 or a salt of said compound.

22. The compound of claim 21, wherein  $R_1$  is methyl.

23. A compound comprising a methanocarbo-cyclic analog of  
 a chemically modified adenosine or uradine wherein said  
 compound is a P2 receptor ligand; or a salt of said compound.

15 24. The compound of claim 23, wherein the compound is a  
 P2 receptor agonist.

25. The compound of claim 23, wherein the compound is a  
 P2 receptor antagonist.

26. The compound of claim 22, wherein said P2 receptor  
 20 is selected from the group consisting of P2Y and P2X.

27. The compound of claim 22, wherein said P2 receptor is a P2Y receptor.

28. The compound of claim 22, wherein said P2 receptor is a P2Y1 receptor.

5 29. The compound of claim 22, wherein said P2 receptor is a P2X receptor.

30. A compound comprising a methanocarboxylic analog of a chemically modified adenosine or uridine wherein said compound is a P1 receptor ligand; or a salt of said compound.

10 31. The compound of claim 30, wherein the compound is a P1 receptor agonist.

32. The compound of claim 30, wherein the compound is a P1 receptor antagonist.

15 33. The compound of claim 30, wherein said P1 receptor is selected from the group consisting of A<sub>1</sub>, A<sub>2A</sub>, and A<sub>3</sub>.

34. The compound of claim 30, wherein said P1 receptor is A<sub>1</sub> receptor.

35. The compound of claim 30, wherein said P1 receptor is A<sub>3</sub> receptor.

20 36. A method of treating or preventing in a mammal a disease, state, or condition that responds to an adenosine, ATP, or UTP receptor agonist or antagonist comprising administering to the mammal a compound of any of any of claims 1-36.

25 37. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of any of claims 1-36.

33. The use of a compound of any of claims 1-36 as a medicament.

34. The use of a methanocarba analog in the manufacture of a medicament for the treatment or prevention in a mammal a  
5 disease state, or condition that responds to an adenosine, ATP, UTP receptor agonist or antagonist.

35. A method for the treatment of airway diseases, cancer, cardiac arrhythmia, cardiac ischemia, epilepsy, Huntington's Disease, immunodeficient disorders, inflammatory  
10 disorders, neonatal hypoxia, neurodegenerative, pain, Parkinson's Disease, renal failure, schizophrenia, sleep disorders, stroke, thrombosis, urinary incontinence, diabetes, psoriasis, septic shock, brain trauma, glaucoma, or congestive heart failure in individuals in need of such treatment  
15 comprising contacting an effective quantity of a compound of any of claims 1-36.



## INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 01/00981

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D471/04 C07D487/04 C07D239/54 C07D239/56 C07D239/58  
 A61P29/00 A61P35/00 A61K31/505 A61K31/52  
 //(C07D487/04, 239:00, 235:00)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>SIDDIQUI M A ET AL: "SYNTHESIS, CONFORMATIONAL ANALYSIS, AND BIOLOGICAL ACTIVITY OF A RIGID CARBOCYCLIC ANALOGUE OF 2'-DEOXYARISTEROMYCIN BUILT ON A BICYCLO[3.1.0]HEXANE TEMPLATE" NUCLEOSIDES &amp; NUCLEOTIDES, US, MARCEL DEKKER, INC, vol. 15, no. 1/03, 1996, pages 235-250, XP000615548 ISSN: 0732-8311 cpds 1-4, 14</p> <p style="text-align: center;">--- -/-</p>	9-22, 37, 38

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*G\* document member of the same patent family

Date of the actual completion of the international search

7 May 2001

Date of mailing of the international search report

15/06/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Fritz, M

## INTERNATIONAL SEARCH REPORT

Int lional Application No  
PCT/US 01/00981

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KATAGIRI N ET AL: "The first synthesis of a 2',3'-methano carbocyclic nucleoside" TETRAHEDRON LETTERS,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 40, no. 51, 17 December 1999 (1999-12-17), pages 9069-9072, XP004184808 ISSN: 0040-4039 cpds. B-D,13	9-22,37, 38
X	--- DYATKINA N ET AL: "Modified triphosphates of carbocyclic nucleoside analogues: synthesis, stability towards alkaline phosphatase and substrate properties for some DNA polymerases" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 6, no. 22, 19 November 1996 (1996-11-19), pages 2639-2642, XP004135866 ISSN: 0960-894X Cpds. 6-8	9-20,37, 38
X	--- WO 95 08541 A (US HEALTH) 30 March 1995 (1995-03-30) cpds. 5,13-16,7-9,18-22	9-22,37, 38
X	--- WO 95 03304 A (MERRELL DOW PHARMA) 2 February 1995 (1995-02-02) the whole document	9-22,37, 38
X	--- EP 0 577 558 A (CIBA GEIGY AG) 5 January 1994 (1994-01-05) compounds (I), (Ia) claims	9-22,37, 38
X	--- US 5 840 728 A (RODRIGUEZ JUAN B ET AL) 24 November 1998 (1998-11-24) examples; claims	9-22,37, 38
X	--- WO 98 05662 A (US HEALTH) 12 February 1998 (1998-02-12) Schemes; examples	9-20,37, 38
X	--- US 5 629 454 A (RODRIGUEZ JUAN B ET AL) 13 May 1997 (1997-05-13) examples	9-22,37, 38
	--- -/--	

## INTERNATIONAL SEARCH REPORT

Int lional Application No

PCT/US 01/00981

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>LAK S J ET AL: "Use of a Cyclic Sulfite as an Epoxide Surrogate in the Regioselective Synthesis of a Carbocyclic Ring-Enlarged 4@?,1'a-Methano Oxetanocin Analogue"</p> <p>TETRAHEDRON LETTERS,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 37, no. 14, 1 April 1996 (1996-04-01), pages 2353-2356, XP004029940 ISSN: 0040-4039 Cpds. 2,4,6,17-18</p>	9-22,37,38
X	<p>V E MARQUEZ ET AL: "Nucleosides with a Twist. Can Fixed Forms of Sugar Ring Pucker Influence Biological Activity in Nucleosides and Oligonucleotides ?"</p> <p>JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 39, 13 September 1996 (1996-09-13), pages 3739-3747, XP002094300 ISSN: 0022-2623 cpds. 7-13</p>	9-22,37,38
X	<p>V. E. MARQUEZ ET AL.: "HIV-1 Reverse Transcriptase Can Discriminate between Two Conformationally Locked Carbocyclic AZT Triphosphate Analogues"</p> <p>JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 120, 8 October 1997 (1997-10-08) - 17 March 1998 (1998-03-17), pages 2780-2789, XP000996607 Washington Cpds. 1-3,6-11</p>	21,22,37,38
X	<p>A. EZZITOUNI ET AL.: "Conformationally locked carbocyclic nucleosides built on a bicyclo'3.1.0!hexane template with a fixed Southern conformation. Synthesis and antiviral activity"</p> <p>JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS, vol. 1, 24 June 1996 (1996-06-24) - 1997, pages 1073-1078, XP000996608 Letchworth, GB cpds. 23-24,28</p>	9-22,37,38

-/--

## INTERNATIONAL SEARCH REPORT

Int. Patent Application No.

PCT/US 01/00981

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	V. E. MARQUEZ ET AL.: "Synthesis of Conformationally Restricted Carbocyclic Nucleosides: The Role of the O(4')-Atom in the Key Hydration Step of Adenosine Deaminase" HELVETICA CHIMICA ACTA, vol. 82, 23 August 1999 (1999-08-23), pages 2119-2129, XP000099613 Basel, CH cpds. 8-10,20	9-20,37, 38
X	K. J. SHIN ET AL.: "Construction of the Bicyclo[3.1.0]hexane Template of a Conformationally Locked Carbocyclic Adenosine via an Olefin Keto-Carbene Cycloaddition" JOURNAL OF ORGANIC CHEMISTRY, vol. 65, 15 November 1999 (1999-11-15) - 14 March 2000 (2000-03-14), pages 2172-2178, XP000996614 Washington, USA cpds. 1-4	9-20,37, 38
X	H. R. MOON: "Synthesis of Cyclopropyl-Fused Carbocyclic Nucleosides via the Regioselective Opening of Cyclic Sulfites" JOURNAL OF ORGANIC CHEMISTRY, vol. 64, 4 January 1999 (1999-01-04) - 6 June 1999 (1999-06-06), pages 4733-4741, XP000996615 Washington, USA cpds. 18-20,3a,3c	9-22,37, 38
X	A. EZZITOUNI: "(1S,2R)-'(Benzyloxy)methylcyclopent-3-en-ol. A versatile Synthon for the Preparation of 4',1'a-Methano- and 1',1'a-Methanocarbocyclic Nucleosides" JOURNAL OF ORGANIC CHEMISTRY, vol. 62, 13 November 1996 (1996-11-13) - 1997, pages 4870-4873, XP000996616 Washington, USA cpds.1,2,16	9-22,37, 38

-/--

## INTERNATIONAL SEARCH REPORT

Int ional Application No

PCT/US 01/00981

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	K.-H. ALTMANN ET AL.: "4',6'-Methano-Carbocyclic Thymidine: A Conformationally Constrained Building Block for Oligonucleotides" TETRAHEDRON LETTERS, vol. 35, no. 15, 24 January 1994 (1994-01-24) - 14 February 1997 (1997-02-14), pages 2331-2334, XP000996351 AMSTERDAM cpd. 5	21,22, 37,38
X	A. EZZITOUNI ET AL.: "A Simple Approach to 1',1'a-Methano Carbocyclic Thymidine" J. CHEM. SOCIETY, CHEM. COMM., 28 March 1995 (1995-03-28), pages 1345-1346, XP000996358 Letchworth, GB Cpds. 1,2	21,22, 37-39
X	F. THEIL ET AL.: "Chemoenzymatic synthesis of carbocyclic nucleoside analogues with bicyclo[3.1.0]hexyl residues" J. CHEM. SOC., PERKIN TRANS., vol. 1, 2 August 1995 (1995-08-02) - 15 September 1995 (1995-09-15), pages 255-258, XP000996355 Letchworth, GB cpd. 8	9-20,37, 38
X	J. B. RODRIGUEZ ET AL.: "Synthesis of Cyclopropane-fused Dideoxycarbocyclic Nucleosides Structurally Related to Neoplanocin C" TETRAHEDRON LETTERS, vol. 34, no. 9, 8 - 30 July 1993, pages 6233-6236, XP000996359 Amsterdam, NL cpds. 5,7-8,10,18-20	9-22,37, 38
X	V. E. MARQUEZ ET AL.: "Conformational Analysis of Nucleosides Constructed on a Bicyclo[3.1.0]hexane Template. Structure-antiviral Activity Analysis for the Northern and Southern Hemispheres of the Pseudorotational Cycle " NUCLEOSIDES & NUCLEOTIDES, vol. 16, no. 7-9, 1997, pages 1431-1434, XP000996269 cpds. 3,7	9-20, 37-39

-/--

## INTERNATIONAL SEARCH REPORT

 Int ional Application No  
 PCT/US 01/00981

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	V. E. MARQUEZ: "Conformationally restricted Nucleosides. The reaction of adenosine deaminase with substrates built on a bicyclo[3.2.1]hexane template " NUCLEOSIDES & NUCLEOTIDES, vol. 18, no. 4-5, 1991, pages 521-530, XP000996270 Cpds. 1,4-6	9-20, 37-39
X	L. S. JEONG ET AL.: "Synthesis and Anti-HIV activity of carbocyclic ring-enlarged 4',1'-methano oxetanocin analogues" NUCLEOSIDES & NUCLEOTIDES, vol. 16, no. 7-9, 1997, pages 1059-1062, XP000996284 Cpds. 12-14,16-22	9-22,37, 38
X	K.-H. ALTMANN ET AL.: "1',6'-Methano Carbocyclic Thymidine: Synthesis, X-ray Crystal Structure, and Effect on Nucleic Acid Duplex Stability" TETRAHEDRON LETTERS, vol. 35, no. 41, 1994, pages 7625-7628, XP000996525 compounds 1,2	21,22, 37,38
X	J. B. RODRIGUEZ ET AL.: "Conformationally Locked Nucleoside Analogues. Synthesis of Dideoxycarbocyclic Nucleoside Analogues Structurally Related to Neplanocin C" J. MED. CHEM., vol. 37, 1 June 1994 (1994-06-01), pages 3389-3399, XP000996507 compounds 3,7,9,12,23,25,26,28,29,30,32,33	9-22,37, 38
X	US 4 954 504 A (CHEN JEN ET AL) 4 September 1990 (1990-09-04) abstract Compounds (I) column 1, line 20 - line 24	9-20, 37-39
X	US 5 063 233 A (CHEN JEN ET AL) 5 November 1991 (1991-11-05) Compounds (I) abstract column 1, line 21 - line 26	9-20, 37-39
	--- -/--	

## INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 01/00981

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	JACOBSON K A ET AL: "ADENOSINE RECEPTORS: PHARMACOLOGY, STRUCTURE-ACTIVITY RELATIONSHIPS, AND THERAPEUTIC POTENTIAL" JOURNAL OF MEDICINAL CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. WASHINGTON, vol. 35, no. 3, 7 February 1992 (1992-02-07), pages 407-422, XP002038897 ISSN: 0022-2623 cited in the application the whole document -----	39

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## Continuation of Box I.1

Although claims 36, 40 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

## Continuation of Box I.2

Claims Nos.: 1-8,23-35

Present claims 1-8,23-35 relate to an extremely large number of possible compounds. In fact, the expression "chemically modified" contains so many possible permutations of the vbasic chemical structure that a lack of clarity (and/or conciseness) within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible.

Consequently, the search has been carried out for those parts of the application which do appear to be clear (and/or concise), namely claims 9-22 and 37-39 which are the only claims being supported by the description.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/00981

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9508541 A	30-03-1995	AT 160340 T AU 677441 B AU 7842094 A CA 2172534 A DE 69406943 D DE 69406943 T DK 720604 T EP 0720604 A ES 2111960 T GR 3026166 T JP 9502986 T US 5629454 A US 5869666 A	15-12-1997 24-04-1997 10-04-1995 30-03-1995 02-01-1998 07-05-1998 27-07-1998 10-07-1996 16-03-1998 29-05-1998 25-03-1997 13-05-1997 09-02-1999
WO 9503304 A	02-02-1995	AT 176668 T AU 683287 B AU 7316794 A CA 2166692 A DE 69416518 D DE 69416518 T DK 710239 T EP 0710239 A ES 2132419 T GR 3029454 T JP 9500643 T ZA 9405246 A	15-02-1999 06-11-1997 20-02-1995 02-02-1995 25-03-1999 01-07-1999 20-09-1999 08-05-1996 16-08-1999 28-05-1999 21-01-1997 20-03-1995
EP 0577558 A	05-01-1994	CA 2099712 A JP 6100562 A MX 9303965 A US 5461152 A US 5610300 A US 5700920 A	02-01-1994 12-04-1994 29-04-1994 24-10-1995 11-03-1997 23-12-1997
US 5840728 A	24-11-1998	NONE	
WO 9805662 A	12-02-1998	AU 6766496 A	25-02-1998
US 5629454 A	13-05-1997	US 5869666 A AT 160340 T AU 677441 B AU 7842094 A CA 2172534 A DE 69406943 D DE 69406943 T DK 720604 T EP 0720604 A ES 2111960 T GR 3026166 T JP 9502986 T WO 9508541 A	09-02-1999 15-12-1997 24-04-1997 10-04-1995 30-03-1995 02-01-1998 07-05-1998 27-07-1998 10-07-1996 16-03-1998 29-05-1998 25-03-1997 30-03-1995
US 4954504 A	04-09-1990	US 5063233 A AU 608258 B AU 8119387 A CA 1288431 A DD 273833 A DK 596087 A	05-11-1991 28-03-1991 19-05-1988 03-09-1991 29-11-1989 15-05-1988

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/00981

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4954504 A		EP 0267878 A	18-05-1988
		FI 874982 A	15-05-1988
		HU 45057 A,B	30-05-1988
		JP 63135384 A	07-06-1988
		NO 874749 A,B,	16-05-1988
		NZ 222527 A	28-08-1990
		PH 25044 A	28-01-1991
		PT 86120 A,B	01-12-1987
		ZA 8708527 A	16-05-1988
US 5063233 A	05-11-1991	US 4954504 A	04-09-1990
		AU 608258 B	28-03-1991
		AU 8119387 A	19-05-1988
		CA 1288431 A	03-09-1991
		DD 273833 A	29-11-1989
		DK 596087 A	15-05-1988
		EP 0267878 A	18-05-1988
		FI 874982 A	15-05-1988
		HU 45057 A,B	30-05-1988
		JP 63135384 A	07-06-1988
		NO 874749 A,B,	16-05-1988
		NZ 222527 A	28-08-1990
		PH 25044 A	28-01-1991
		PT 86120 A,B	01-12-1987
		ZA 8708527 A	16-05-1988